JPCR Home
Honorable Editors
John E Nathan
University of Alabama
USA View Profile
Research Interest:
Pharmacological and Non-Pharmacological Management of Challenging behavior of Children; Exploring the Efficacy and Safety of various Pharmacotherapeutic regimens for managing challenging childhood dental anxiety and uncooperative behavior
Pharmacological and Non-Pharmacological Management of Challenging behavior of Children; Exploring the Efficacy and Safety of various Pharmacotherapeutic regimens for managing challenging childhood dental anxiety and uncooperative behavior
Profile:
Nathan received his DDS from Northwestern University in 1975 and completed a one year General Practice Residency at the V.A. Hospital in Chicago in 1976. He completed the three-year Residency Program in Pediatric Dentistry and M.Dent Sc degree from the University of Connecticut in 1979. He served as Assistant Professor of Pediatric Dentistry from 1979-86 and as Postgraduate Program Director at the University of Illinois from 1983-86, while serving as Visiting Assistant Professor, Depts. of Pediatrics and Surgery at Rush University Medical College from 1979-87. He is a Diplomate, American Board of Pediatric Dentistry, Fellow and Master, the American Society of Dentistry for Children, Fellow, American Academy of Pediatric Dentistry; he served as Consultant to the American Board of Pediatric Dentistry and Site Review consultant for the Council on Dental Accreditation. Nathan currently serves as Adjunct Professor, Depts. of Pediatric Dentistry, University of Alabama, Birmingham, and Case Western Reserve University, Cleveland. He also serves as Clinical Associate Professor, Dept. of Otolaryngology, Northwestern University Feinberg School of Medicine; Nathan currently serves on the editorial board of four journals and is Editor-in-Chief of the Journal of Pediatrics and Neonatal, Nursing and the Journal of Otolaryngology and Rhinology. He is attending house staff at Childrens Memorial Hospital/Robert and Ann Lurie Childrens Hospital of Chicago since 1990. Nathan has been engaged in private practice limited to pediatric dentistry in Oak Brook and St. Charles, IL since 1986. He serves as a national expert, lecturer and spokesperson for the American Academy of Pediatric Dentistry on child behavioral guidance and the pharmacological management of challenging pediatric dental patients. He is extensively published in this arena.
×
Nathan received his DDS from Northwestern University in 1975 and completed a one year General Practice Residency at the V.A. Hospital in Chicago in 1976. He completed the three-year Residency Program in Pediatric Dentistry and M.Dent Sc degree from the University of Connecticut in 1979. He served as Assistant Professor of Pediatric Dentistry from 1979-86 and as Postgraduate Program Director at the University of Illinois from 1983-86, while serving as Visiting Assistant Professor, Depts. of Pediatrics and Surgery at Rush University Medical College from 1979-87. He is a Diplomate, American Board of Pediatric Dentistry, Fellow and Master, the American Society of Dentistry for Children, Fellow, American Academy of Pediatric Dentistry; he served as Consultant to the American Board of Pediatric Dentistry and Site Review consultant for the Council on Dental Accreditation. Nathan currently serves as Adjunct Professor, Depts. of Pediatric Dentistry, University of Alabama, Birmingham, and Case Western Reserve University, Cleveland. He also serves as Clinical Associate Professor, Dept. of Otolaryngology, Northwestern University Feinberg School of Medicine; Nathan currently serves on the editorial board of four journals and is Editor-in-Chief of the Journal of Pediatrics and Neonatal, Nursing and the Journal of Otolaryngology and Rhinology. He is attending house staff at Childrens Memorial Hospital/Robert and Ann Lurie Childrens Hospital of Chicago since 1990. Nathan has been engaged in private practice limited to pediatric dentistry in Oak Brook and St. Charles, IL since 1986. He serves as a national expert, lecturer and spokesperson for the American Academy of Pediatric Dentistry on child behavioral guidance and the pharmacological management of challenging pediatric dental patients. He is extensively published in this arena.
Sergey B Zhuplatov
AstraZeneca
USA View Profile
Research Interest:
Cardiovascular, Metabolic and Internal Medicine within of the ischemic heart disease and diabetes complications prevention and treatment.
Cardiovascular, Metabolic and Internal Medicine within of the ischemic heart disease and diabetes complications prevention and treatment.
Profile:
Zhuplatov is a successful Medical Scientist, the leader with a Metabolic/ CV Medical Affairs and Medical Development experience within the Global pharmaceutical industry. He was graduated in Russian Izhevsk State Medical Academy. After a fellowship in Internal Medicine and Endocrinology he continued hi completed Ph.D. dissertation in Cardiology with the Topic “Prevention of the Ischemic Heart Progression in Diabetics by extracorporal purification methods”. He practiced Endocrinology and Internal Medicine being a Clinical Assistant Professor for 12 years. He emigrated to the USA in 2002 and continued his scientific work as a preclinical scientist in the University of Utah Medical School. He published several scientific manuscripts in the area of Transplantology and Oncology at this time. However, he changed his job in 2008 and started his career in the Pharmaceutical Industry. As a Medical Science Liaison, he has communicated with brightest scientific and clinical leaders in Diabetology for 5 years and has been promoted to the Director role in the US Medical Affairs Headquarter of the Global Pharmaceutical Company. He is working in the Strategy and Development of Anti-Diabetic drugs and use his significant experience in the research planning, results evaluation, and Medical representation of Anti-Diabetic drugs.
×
Zhuplatov is a successful Medical Scientist, the leader with a Metabolic/ CV Medical Affairs and Medical Development experience within the Global pharmaceutical industry. He was graduated in Russian Izhevsk State Medical Academy. After a fellowship in Internal Medicine and Endocrinology he continued hi completed Ph.D. dissertation in Cardiology with the Topic “Prevention of the Ischemic Heart Progression in Diabetics by extracorporal purification methods”. He practiced Endocrinology and Internal Medicine being a Clinical Assistant Professor for 12 years. He emigrated to the USA in 2002 and continued his scientific work as a preclinical scientist in the University of Utah Medical School. He published several scientific manuscripts in the area of Transplantology and Oncology at this time. However, he changed his job in 2008 and started his career in the Pharmaceutical Industry. As a Medical Science Liaison, he has communicated with brightest scientific and clinical leaders in Diabetology for 5 years and has been promoted to the Director role in the US Medical Affairs Headquarter of the Global Pharmaceutical Company. He is working in the Strategy and Development of Anti-Diabetic drugs and use his significant experience in the research planning, results evaluation, and Medical representation of Anti-Diabetic drugs.
Luiz Fernando Ferrari
School of Dentistry
USA View Profile
Research Interest:
His current research focuses the investigation of the cellular/molecular mechanisms involved in the neuronal painful sensitization, using pre-clinical models. Behavior methods, along with pharmacological tools and interventions to analyze the role of specific genes in nociceptor function are used in his studies to demonstrate the neuronal processes involved in acute and chronic pain. At this moment, his projects investigate the molecular and cellular signaling pathways that participate in the development and/or maintenance of nociceptor sensitization and in the transition from acute to chronic pain. In parallel, the role of sexual dimorphism in the development of pain induced by chronic use of opioids has also been part of his studies. He believes that his experience with different animal behavior models allows him to better understand the neurophysiology of pain, which might contribute for the development of more specific pharmacological therapies.
His current research focuses the investigation of the cellular/molecular mechanisms involved in the neuronal painful sensitization, using pre-clinical models. Behavior methods, along with pharmacological tools and interventions to analyze the role of specific genes in nociceptor function are used in his studies to demonstrate the neuronal processes involved in acute and chronic pain. At this moment, his projects investigate the molecular and cellular signaling pathways that participate in the development and/or maintenance of nociceptor sensitization and in the transition from acute to chronic pain. In parallel, the role of sexual dimorphism in the development of pain induced by chronic use of opioids has also been part of his studies. He believes that his experience with different animal behavior models allows him to better understand the neurophysiology of pain, which might contribute for the development of more specific pharmacological therapies.
Profile:
Luiz Fernando Ferrari got his D.D.S. degree from the School of Dentistry in the University of Sao Paulo in 1996. He worked in his own office, in Brazil, performing general dentistry, oral surgery and temporomandibular joint dysfunction/orofacial pain treatment. However, to learn and understand more about pain physiology and pharmacology he went to the Medical School in the University of Sao Paulo at Ribeirao Preto. There, at the Department of Pharmacology, he got his Master’s and Ph.D. in Pharmacology/Neuroscience, researching the cellular and molecular mechanisms involved in the generation and maintenance of pain, and therapeutic strategies for treatment. He also worked as a Professor of Pharmacology & Therapeutics and Neurophysiology of Pain in the School of Dentistry in University of Sao Paulo at Ribeirao Preto, and was part of the team of Professors in the Temporomandibular Joint Dysfunction and Orofacial Pain Specialization Course for several years, teaching and supervising students of the School of Dentistry in the clinic. Currently, he is working in the University of California at San Francisco, as a Research Pharmacologist, investigating the mechanisms involved in the transition from acute to chronic pain, as well as the neural basis of the chronic pain induced by inflammation, stress and as side effect of therapeutic drugs.
×
Luiz Fernando Ferrari got his D.D.S. degree from the School of Dentistry in the University of Sao Paulo in 1996. He worked in his own office, in Brazil, performing general dentistry, oral surgery and temporomandibular joint dysfunction/orofacial pain treatment. However, to learn and understand more about pain physiology and pharmacology he went to the Medical School in the University of Sao Paulo at Ribeirao Preto. There, at the Department of Pharmacology, he got his Master’s and Ph.D. in Pharmacology/Neuroscience, researching the cellular and molecular mechanisms involved in the generation and maintenance of pain, and therapeutic strategies for treatment. He also worked as a Professor of Pharmacology & Therapeutics and Neurophysiology of Pain in the School of Dentistry in University of Sao Paulo at Ribeirao Preto, and was part of the team of Professors in the Temporomandibular Joint Dysfunction and Orofacial Pain Specialization Course for several years, teaching and supervising students of the School of Dentistry in the clinic. Currently, he is working in the University of California at San Francisco, as a Research Pharmacologist, investigating the mechanisms involved in the transition from acute to chronic pain, as well as the neural basis of the chronic pain induced by inflammation, stress and as side effect of therapeutic drugs.
Kristin M Wilcox
Carrol County Health Department
USA View Profile
Research Interest:
Evaluating the pharmacological mechanisms that contribute to the abuse liability and the cognitive effects of central nervous system compounds; Attention Deficit Hyperactivity Disorder; how the combination of impulsive behavior and stimulant drug treatment may predispose children with attention deficit disorder to abuse other stimulant drugs like cocaine.
Evaluating the pharmacological mechanisms that contribute to the abuse liability and the cognitive effects of central nervous system compounds; Attention Deficit Hyperactivity Disorder; how the combination of impulsive behavior and stimulant drug treatment may predispose children with attention deficit disorder to abuse other stimulant drugs like cocaine.
Profile:
Throughout her academic and professional career she has gained extensive experience with both behavioral and neurochemical tools that are well suited to the study of central nervous system drugs. She has a PhD. in pharmacology from the University of Mississippi Medical Center in Jackson, Mississippi, and more than 20 years as a researcher in the field of behavioral pharmacology/ neuroscience. Under the direction of Dr. William Woolverton at the University of Mississippi she studied the relationship between neurochemical mechanisms and behavioral mechanisms involved in the abuse liability of psychomotor stimulants in macaques. After earning her PhD. she worked in the lab of Dr. Leonard Howell at Emory University where she continued to study the pharmacological effects of cocaine and related compounds, assessed during neuroimaging using positron emission tomography, mediating abuse liability in macaques. After the completion of her post doctoral fellowship at Emory University she went to work with Dr. Michael Weed at Johns Hopkins University in Baltimore, Maryland. She studied the effects of chronic oral methylphenidate and amphetamine on physiological development, circadian rhythms, cognitive functioning, and neurochemistry in preadolescent macaques at therapeutically relevant doses for treatment of Attention Deficit Hyperactivity Disorder in children. During her scientific career she has continually evolved by learning new skills to enhance her drug abuse research background and has studied both well-known and novel compounds. She has experience with experimental design, publishing her research in peer reviewed scientific journals, writing grant proposals submitted to the National Institutes of Health, and presenting my research to large groups at international scientific meetings.
×
Throughout her academic and professional career she has gained extensive experience with both behavioral and neurochemical tools that are well suited to the study of central nervous system drugs. She has a PhD. in pharmacology from the University of Mississippi Medical Center in Jackson, Mississippi, and more than 20 years as a researcher in the field of behavioral pharmacology/ neuroscience. Under the direction of Dr. William Woolverton at the University of Mississippi she studied the relationship between neurochemical mechanisms and behavioral mechanisms involved in the abuse liability of psychomotor stimulants in macaques. After earning her PhD. she worked in the lab of Dr. Leonard Howell at Emory University where she continued to study the pharmacological effects of cocaine and related compounds, assessed during neuroimaging using positron emission tomography, mediating abuse liability in macaques. After the completion of her post doctoral fellowship at Emory University she went to work with Dr. Michael Weed at Johns Hopkins University in Baltimore, Maryland. She studied the effects of chronic oral methylphenidate and amphetamine on physiological development, circadian rhythms, cognitive functioning, and neurochemistry in preadolescent macaques at therapeutically relevant doses for treatment of Attention Deficit Hyperactivity Disorder in children. During her scientific career she has continually evolved by learning new skills to enhance her drug abuse research background and has studied both well-known and novel compounds. She has experience with experimental design, publishing her research in peer reviewed scientific journals, writing grant proposals submitted to the National Institutes of Health, and presenting my research to large groups at international scientific meetings.
David M Benjamin
Northeastern University School of Pharmacy
USA View Profile
Research Interest:
Clinical Pharmacology; Reducing Medication Errors; Pharmacokinetics; Opioid Pharmacology; Synthetic Cannabinoids; DUI Ambien and Neuropsychopharmacology
Clinical Pharmacology; Reducing Medication Errors; Pharmacokinetics; Opioid Pharmacology; Synthetic Cannabinoids; DUI Ambien and Neuropsychopharmacology
Profile:
David Wallace joined Oklahoma State University Center for Health Sciences in 1996 after fellowships at the University of Kentucky and University of Colorado Health Science Center. Since his arrival, he has been actively involved in teaching 1st and 2nd year medical students as well as graduate students in the Biomedical Science, Forensic Science and Veterinary Biomedical Science graduate programs. He has been extensively trained in basic pharmacological & toxicological methods such as radioligand binding, neurotransmitter uptake/release and intracellular assays. Current work focuses on the use of cellular model systems and determining molecular changes in cellular signaling cascades which would promote tumor formation and growth.
×
David Wallace joined Oklahoma State University Center for Health Sciences in 1996 after fellowships at the University of Kentucky and University of Colorado Health Science Center. Since his arrival, he has been actively involved in teaching 1st and 2nd year medical students as well as graduate students in the Biomedical Science, Forensic Science and Veterinary Biomedical Science graduate programs. He has been extensively trained in basic pharmacological & toxicological methods such as radioligand binding, neurotransmitter uptake/release and intracellular assays. Current work focuses on the use of cellular model systems and determining molecular changes in cellular signaling cascades which would promote tumor formation and growth.
Dr. Franz J. Hock
FJH Safety Pharm Consulting, Germany; Altstadt 19, D-64807 Die burg
Germany View Profile
Research Interest:
Behavioral pharmacology studies in animals; Cardiovascular pharmacology in animals and Drug safety studies in general
Behavioral pharmacology studies in animals; Cardiovascular pharmacology in animals and Drug safety studies in general
Profile:
Since retiring from Aventis in 2002, Dr. Hock has leveraged his experience as a freelance consultant specializing in Safety Pharmacology. he was a research scientist at Hoechst, Hoechst Marion Roussel and Aventis from 1976–2002. He initially worked on methods in general pharmacology and nephrology, before becoming Head of a Laboratory devoted to pharmacological methods for drugs influencing memory and learning. He was ultimately Head of Laboratory for General/Safety Pharmacology at the Frankfurt site of Aventis Pharma Deutschland GmbH. Dr. Hock received his MSc in Neurobiology from the Technical University Darmstadt and his DSc in Zoology form the University Kassel, Department of Biology, Institute of Neuroethology and Biocybernetics. He received the degree of Fachpharmakologe DGPT ("certified expert pharmacology") in 1981. In 1983, he spent a sabbatical year at the University of California, Irvine, at the Center for the Neurobiology of Learning and Memory (Director Prof. Dr. James L. McGaugh). He lectured for several years to students in Biology at the University of Kassel und the Technical University of Darmstadt. He has published over 100 original papers on methods in pharmacology and on new compounds. Furthermore, he held 28 patent applications, to protect or broaden the application of lead structures. He is currently a member of the Task Force General/Safety Pharmacology German/Swiss Pharmaceutical Companies. A member of several national and international scientific societies, Dr. Hock is a founding member of “Safety Pharmacology Society”, “Neurowissenschaftliche Gesellschaft e.V.” and “European Behavioural Pharmacology Society”. Since several years, he served as a member of the Program Committee of the Safety Pharmacology Society. He is member of several domestic and international scientific societies
×
Since retiring from Aventis in 2002, Dr. Hock has leveraged his experience as a freelance consultant specializing in Safety Pharmacology. he was a research scientist at Hoechst, Hoechst Marion Roussel and Aventis from 1976–2002. He initially worked on methods in general pharmacology and nephrology, before becoming Head of a Laboratory devoted to pharmacological methods for drugs influencing memory and learning. He was ultimately Head of Laboratory for General/Safety Pharmacology at the Frankfurt site of Aventis Pharma Deutschland GmbH. Dr. Hock received his MSc in Neurobiology from the Technical University Darmstadt and his DSc in Zoology form the University Kassel, Department of Biology, Institute of Neuroethology and Biocybernetics. He received the degree of Fachpharmakologe DGPT ("certified expert pharmacology") in 1981. In 1983, he spent a sabbatical year at the University of California, Irvine, at the Center for the Neurobiology of Learning and Memory (Director Prof. Dr. James L. McGaugh). He lectured for several years to students in Biology at the University of Kassel und the Technical University of Darmstadt. He has published over 100 original papers on methods in pharmacology and on new compounds. Furthermore, he held 28 patent applications, to protect or broaden the application of lead structures. He is currently a member of the Task Force General/Safety Pharmacology German/Swiss Pharmaceutical Companies. A member of several national and international scientific societies, Dr. Hock is a founding member of “Safety Pharmacology Society”, “Neurowissenschaftliche Gesellschaft e.V.” and “European Behavioural Pharmacology Society”. Since several years, he served as a member of the Program Committee of the Safety Pharmacology Society. He is member of several domestic and international scientific societies
Philip P Stashenko
Forsyth Institute & Harvard School of Dental Medicine
USA View Profile
Research Interest:
Host-microbiome interactions in health and disease; Immunotherapies for oral squamous cell carcinoma; Immunity to disseminating dentoalveolar infections; Osteoimmunology; Salivary biomarkers and diagnostics.
Host-microbiome interactions in health and disease; Immunotherapies for oral squamous cell carcinoma; Immunity to disseminating dentoalveolar infections; Osteoimmunology; Salivary biomarkers and diagnostics.
Profile:
Dr. Stashenko received a BA in biology from NYU, and DMD, PhD (immunology), and certificate in endodontics, all from Harvard University. Dr. Stashenko became Senior Member of Staff with tenure at Forsyth Institute in 1989, and founding head of the Department of Cytokine Biology in 1992. He was appointed as Vice President for Research in 2000, a role in which he provided leadership and support for the research enterprise at Forsyth. From 2008-2016 he served as President and CEO of Forsyth. In this role he was responsible for the oversight of all institutional operations, including research, finance, fundraising, technology transfer, business development, education and community outreach. He is jointly appointed in the Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine (HSDM) where he teaches and mentors research students. Dr. Stashenko‘s ongoing research program focuses on immunology, mechanisms of inflammatory bone resorption and interactions between the host and the oral microbiome in health and various diseases. He was identified as being among the top 5% of NIH grant recipients over the preceding 25 years (2005). He is the author of more than 200 scientific articles, abstracts, reviews and book chapters. He has served on the National Advisory Council for the NIDCR/NIH, and as a grant reviewer for many NIH study sections. His numerous awards include membership in Phi Beta Kappa, research fellowships from the NIH, and the Distinguished Faculty Award from Harvard School of Dental Medicine.
×
Dr. Stashenko received a BA in biology from NYU, and DMD, PhD (immunology), and certificate in endodontics, all from Harvard University. Dr. Stashenko became Senior Member of Staff with tenure at Forsyth Institute in 1989, and founding head of the Department of Cytokine Biology in 1992. He was appointed as Vice President for Research in 2000, a role in which he provided leadership and support for the research enterprise at Forsyth. From 2008-2016 he served as President and CEO of Forsyth. In this role he was responsible for the oversight of all institutional operations, including research, finance, fundraising, technology transfer, business development, education and community outreach. He is jointly appointed in the Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine (HSDM) where he teaches and mentors research students. Dr. Stashenko‘s ongoing research program focuses on immunology, mechanisms of inflammatory bone resorption and interactions between the host and the oral microbiome in health and various diseases. He was identified as being among the top 5% of NIH grant recipients over the preceding 25 years (2005). He is the author of more than 200 scientific articles, abstracts, reviews and book chapters. He has served on the National Advisory Council for the NIDCR/NIH, and as a grant reviewer for many NIH study sections. His numerous awards include membership in Phi Beta Kappa, research fellowships from the NIH, and the Distinguished Faculty Award from Harvard School of Dental Medicine.
Klaus R Krauser
Senior Executive Expert in Nonclinical Development
USA View Profile
Research Interest:
Safety Pharmacology; Pharmaceuticals; Medical Devices
Safety Pharmacology; Pharmaceuticals; Medical Devices
Profile:
Dr. Krauser has more than 30 years of experience in nonclinical drug development and preclinical safety testing and assessment of both small molecule and large molecule drugs of different formats, as well as of industrial chemicals and medical devices. Most recently he served as Senior Director Non-Clinical Innovation and R&D Strategy at Shire, previously Baxalta, where he was representing Non-Clinical Development as the non-clinical interface within R&D and with other functions at the Cambridge, MA, innovation center. Before he was Vice President Drug Safety at Thesan Pharmaceuticals in Carlsbad, CA, and Vice President Preclinical Development at Berg Health, Framingham, MA, and before that he represented Nonclinical Safety at the Novartis Biotherapeutics Development Unit in San Diego, CA. There he contributed nonclinical safety expertise and activities to different biologics projects as member of a co-located team of global development experts.
×
Dr. Krauser has more than 30 years of experience in nonclinical drug development and preclinical safety testing and assessment of both small molecule and large molecule drugs of different formats, as well as of industrial chemicals and medical devices. Most recently he served as Senior Director Non-Clinical Innovation and R&D Strategy at Shire, previously Baxalta, where he was representing Non-Clinical Development as the non-clinical interface within R&D and with other functions at the Cambridge, MA, innovation center. Before he was Vice President Drug Safety at Thesan Pharmaceuticals in Carlsbad, CA, and Vice President Preclinical Development at Berg Health, Framingham, MA, and before that he represented Nonclinical Safety at the Novartis Biotherapeutics Development Unit in San Diego, CA. There he contributed nonclinical safety expertise and activities to different biologics projects as member of a co-located team of global development experts.
Ping Ma
Formulation Scientist
USA View Profile
Research Interest:
Including Oral, Parenteral, and lipid-based nanoparticle drug; Formulation process development and optimization; Lyophilization cycle development and optimization
Including Oral, Parenteral, and lipid-based nanoparticle drug; Formulation process development and optimization; Lyophilization cycle development and optimization
Profile:
Dr. Ping Ma is current a Formulation Scientist at Tolmar Inc. He works on preformulation and formulation development, analytical method validation, manufacturing process optimization and validation of sterile injectable products. Before joining Tolmar, he worked at Hopsira for four years. he has 15 years of research and development experience into various oral, parenteral, and lipid-based nanoparticle drug delivery systems. He authored 25+ scientific publications in the area of formulation development and drug delivery, and 30+ scientific presentations at international conferences. In addition, he serves on Editorial Advisory Board of several drug delivery and pharmaceutical science journals, as well as a reviewer for 10+ scientific journals. he has his Ph.D. degree in Drug Delivery from the University of North Carolina at Chapel Hill.
×
Dr. Ping Ma is current a Formulation Scientist at Tolmar Inc. He works on preformulation and formulation development, analytical method validation, manufacturing process optimization and validation of sterile injectable products. Before joining Tolmar, he worked at Hopsira for four years. he has 15 years of research and development experience into various oral, parenteral, and lipid-based nanoparticle drug delivery systems. He authored 25+ scientific publications in the area of formulation development and drug delivery, and 30+ scientific presentations at international conferences. In addition, he serves on Editorial Advisory Board of several drug delivery and pharmaceutical science journals, as well as a reviewer for 10+ scientific journals. he has his Ph.D. degree in Drug Delivery from the University of North Carolina at Chapel Hill.
Jan M Keppel Hesselink
Institute for Neuropathic Pain
Germany View Profile
Research Interest:
Extensively on Research and Development bottlenecks in pharmaceutical medicine and Biotech, as well as on Autacoid Medicine and on new innovative topical analgesic formulations, among which phenytoin, ketamine and baclofen.
Extensively on Research and Development bottlenecks in pharmaceutical medicine and Biotech, as well as on Autacoid Medicine and on new innovative topical analgesic formulations, among which phenytoin, ketamine and baclofen.
Profile:
Jan M. Keppel Hesselink, MD, MSc, PhD received his MSc in biology (cum laude) at the university of Utrecht; his degree in medicine, MD in Utrecht, his PhD (thesis on Parkinsons disease) at the university of Nijmegen, the Netherlands. Currently working as: 1. Consultant: *due diligence for Investment Management in Biotech and Pharmaceuticals and *R&D advice within the field of drug development in CNS indications. 2. Pain physician and director at the Institute for Neuropathic Pain: www.neuropathy.nl In 1996 he was appointed professor of molecular pharmacology at the university of Witten/Herdecke (Germany). In the same period he was elected as Fellow of the Pharmaceutical Faculty in Medicine (FFPM) in the UK. He worked several years at Bayer AG in Germany as VP CNS and business head CNS worldwide. He became director at Licentec and advisor R&D to the Dutch Royal Academy of Science (KNAW) and institutes, such as the Hubrecht Institute, where he assisted spin-outs. He was CEO of the Academic Medical Centre Amsterdam’s (AMC) institute for antiviral therapy: IATEC. In 2009 he started the Institute for Neuropathic Pain, since then 8 different novel topical analgesic creams have been developed as compounded creams. He holds 2 recent patents on the topical use of phenytoin for the treatment of neuropathic pain. He wrote a number of books in the field of neurology and many book chapters, and published extensively in the fields of neurology, neuropathy, pharmacology, CNS, pharmaceutical medicine, drug development, R&D, pharmacotherapy, pain, analgesia, transdermal and topical treatments. His current focus is on drug development and drug repurposing/repositioning.
×
Jan M. Keppel Hesselink, MD, MSc, PhD received his MSc in biology (cum laude) at the university of Utrecht; his degree in medicine, MD in Utrecht, his PhD (thesis on Parkinsons disease) at the university of Nijmegen, the Netherlands. Currently working as: 1. Consultant: *due diligence for Investment Management in Biotech and Pharmaceuticals and *R&D advice within the field of drug development in CNS indications. 2. Pain physician and director at the Institute for Neuropathic Pain: www.neuropathy.nl In 1996 he was appointed professor of molecular pharmacology at the university of Witten/Herdecke (Germany). In the same period he was elected as Fellow of the Pharmaceutical Faculty in Medicine (FFPM) in the UK. He worked several years at Bayer AG in Germany as VP CNS and business head CNS worldwide. He became director at Licentec and advisor R&D to the Dutch Royal Academy of Science (KNAW) and institutes, such as the Hubrecht Institute, where he assisted spin-outs. He was CEO of the Academic Medical Centre Amsterdam’s (AMC) institute for antiviral therapy: IATEC. In 2009 he started the Institute for Neuropathic Pain, since then 8 different novel topical analgesic creams have been developed as compounded creams. He holds 2 recent patents on the topical use of phenytoin for the treatment of neuropathic pain. He wrote a number of books in the field of neurology and many book chapters, and published extensively in the fields of neurology, neuropathy, pharmacology, CNS, pharmaceutical medicine, drug development, R&D, pharmacotherapy, pain, analgesia, transdermal and topical treatments. His current focus is on drug development and drug repurposing/repositioning.
Keith M Sharrow
Uniformed Services University of the Health Sciences
USA View Profile
Research Interest:
Pharmacological treatment of traumatic brain and eye injury; Drug/drug interactions; Fatty acid metabolism; Behavioral pharmacology; Environmental toxins; Drug delivery device development; Drug supply system issues; US and international drug regulatory issues
Pharmacological treatment of traumatic brain and eye injury; Drug/drug interactions; Fatty acid metabolism; Behavioral pharmacology; Environmental toxins; Drug delivery device development; Drug supply system issues; US and international drug regulatory issues
Profile:
Keith Sharrow has been interested in linking findings in basic research to applicable treatments and therapies to treat human disease. After earning his PhD in the Department of Pharmacology at the University of Kentucky, Sharrow spearheaded efforts at the Walter Reed Army Institute of Research to evaluate several candidate compounds for the treatment of penetrating brain injury. These efforts led to the advancement of several candidates into clinical trials that are ongoing. He then led a team of senior Army environmental chemists in the development of numerous novel analytical techniques to detect toxins in different food source matrices which have been adapted by the US FDA as standard procedures to protect the US food supply. DrSharrow then headed a research group which investigated the effects of omega 3 fatty acids on brain and eye injury in a number of different injury models. And currently he is the Director of Clinical Pharmacology at the Department of Defense’s drug development center for medical countermeasures against chemical and biological warfare agents.
×
Keith Sharrow has been interested in linking findings in basic research to applicable treatments and therapies to treat human disease. After earning his PhD in the Department of Pharmacology at the University of Kentucky, Sharrow spearheaded efforts at the Walter Reed Army Institute of Research to evaluate several candidate compounds for the treatment of penetrating brain injury. These efforts led to the advancement of several candidates into clinical trials that are ongoing. He then led a team of senior Army environmental chemists in the development of numerous novel analytical techniques to detect toxins in different food source matrices which have been adapted by the US FDA as standard procedures to protect the US food supply. DrSharrow then headed a research group which investigated the effects of omega 3 fatty acids on brain and eye injury in a number of different injury models. And currently he is the Director of Clinical Pharmacology at the Department of Defense’s drug development center for medical countermeasures against chemical and biological warfare agents.
Bilal S Abuasal
Food and Drug Administration
USA View Profile
Research Interest:
Clinical Pharmacology; Physiologically Based Pharmacokinetic And Pharmacodynamic Modeling And Simulation (PBPK And PK/PD); Clinical Drug Development in Neurology; Neuro-Clinical Pharmacology; Drug Drug Interaction (DDI) and Clinical Pharmacology Trial Design and Analysis; Biopharmaceutics; Drug Metabolism and Pharmacokinetics
Clinical Pharmacology; Physiologically Based Pharmacokinetic And Pharmacodynamic Modeling And Simulation (PBPK And PK/PD); Clinical Drug Development in Neurology; Neuro-Clinical Pharmacology; Drug Drug Interaction (DDI) and Clinical Pharmacology Trial Design and Analysis; Biopharmaceutics; Drug Metabolism and Pharmacokinetics
Profile:
Bilal S Abuasal is working as a clinical pharmacologist in the office of clinical pharmacology at the US food and drug administration since 2013. He is mainly in clinical drug review and development in the field of neurology and clinical pharmacology trial design and analysis. He has a pharmacy background and completed his doctoral studies and post-doctoral training in the application of Physiologically Based Pharmacokinetic and Pharmacodynamic modeling and simulation (PBPK and PK/PD) in drug development and DDI. He has two years’ experience in the pharmaceutical industry and he is an author of many papers and monographs.
×
Bilal S Abuasal is working as a clinical pharmacologist in the office of clinical pharmacology at the US food and drug administration since 2013. He is mainly in clinical drug review and development in the field of neurology and clinical pharmacology trial design and analysis. He has a pharmacy background and completed his doctoral studies and post-doctoral training in the application of Physiologically Based Pharmacokinetic and Pharmacodynamic modeling and simulation (PBPK and PK/PD) in drug development and DDI. He has two years’ experience in the pharmaceutical industry and he is an author of many papers and monographs.
Bidhan C Bandyopadhyay
Georgetown University
USA View Profile
Research Interest:
To understand the mechanism of Ca2+ signaling / transport in excitable and non-excitable cells; to understand the implications of TRP channelopathies and their possible pathomechanisms using genetic, pharmacological, and translational approaches.
To understand the mechanism of Ca2+ signaling / transport in excitable and non-excitable cells; to understand the implications of TRP channelopathies and their possible pathomechanisms using genetic, pharmacological, and translational approaches.
Profile:
Bandyopadhyay did his Bachelor of Science with Biology major and honors in Physiology and Master of Science in Physiology with Neurophysiology specialization from University of Calcutta, Kolkata, India. He did his PhD in Biochemistry from University of Calcutta, India. During his PhD he also involved in teaching in Medical Schools. He has postdoctoral trainings in Pharmacology at Georgetown University and Molecular biology at University of Maryland (UMD). While in UMD, he cloned and functionally characterized several new TRP channels. He received NIH Fogarty International Research Scientist Award in 2002 and moved to NIDCR/NIH intramural research as a research scientist to find out the role TRP channels in the physiological mechanism of saliva secretion and how it may be disturbed during pathology. During his tenure at NIDCR he made a number of important contributions to the areas of calcium signaling and polarized epithelial cell function and received Staff Recognition Award from Director, NIDCR, NIH.
×
Bandyopadhyay did his Bachelor of Science with Biology major and honors in Physiology and Master of Science in Physiology with Neurophysiology specialization from University of Calcutta, Kolkata, India. He did his PhD in Biochemistry from University of Calcutta, India. During his PhD he also involved in teaching in Medical Schools. He has postdoctoral trainings in Pharmacology at Georgetown University and Molecular biology at University of Maryland (UMD). While in UMD, he cloned and functionally characterized several new TRP channels. He received NIH Fogarty International Research Scientist Award in 2002 and moved to NIDCR/NIH intramural research as a research scientist to find out the role TRP channels in the physiological mechanism of saliva secretion and how it may be disturbed during pathology. During his tenure at NIDCR he made a number of important contributions to the areas of calcium signaling and polarized epithelial cell function and received Staff Recognition Award from Director, NIDCR, NIH.
Kim Lawson
Sheffield Hallam University
UK View Profile
Research Interest:
Fibromyalgia, Potassium channel pharmacology.
Fibromyalgia, Potassium channel pharmacology.
Profile:
Dr. Kim Lawson (BTech(Hons), PhD) is a Senior Lecturer in Pharmacology at Sheffield Hallam University, UK. He received a BTech in pharmacology from University of Bradford (UK) and a PhD in pharmacology from the University of Sunderland (UK) and has an international reputation in Drug Discovery Research, gained in multinational pharmaceutical industries (France: Rhone-Poulenc Sante, Recherche Syntex France; Belgium: Sanofi-Labaz; UK: Reckitt & Colman, British Biotech) and academia. His research interests are focused on the pharmacology of potassium channels and to the identification of pharmacological treatments of fibromyalgia. Kim is regularly invited as a consultant to the pharmaceutical and healthcare industries & affiliated organizations, to talk at public events & scientific conferences and to write expert opinion articles for scientific and clinical journals. He is chair of the Medical Advisory Board of Fibromyalgia Action UK and Patron to Folly Pogs Fibromyalgia Research UK.
×
Dr. Kim Lawson (BTech(Hons), PhD) is a Senior Lecturer in Pharmacology at Sheffield Hallam University, UK. He received a BTech in pharmacology from University of Bradford (UK) and a PhD in pharmacology from the University of Sunderland (UK) and has an international reputation in Drug Discovery Research, gained in multinational pharmaceutical industries (France: Rhone-Poulenc Sante, Recherche Syntex France; Belgium: Sanofi-Labaz; UK: Reckitt & Colman, British Biotech) and academia. His research interests are focused on the pharmacology of potassium channels and to the identification of pharmacological treatments of fibromyalgia. Kim is regularly invited as a consultant to the pharmaceutical and healthcare industries & affiliated organizations, to talk at public events & scientific conferences and to write expert opinion articles for scientific and clinical journals. He is chair of the Medical Advisory Board of Fibromyalgia Action UK and Patron to Folly Pogs Fibromyalgia Research UK.
Anupam Mitra,
University of California Davis
USA View Profile
Research Interest:
Immunopharmacology; Drug development; Cell signaling; Natural medicinal product validation
Immunopharmacology; Drug development; Cell signaling; Natural medicinal product validation
Profile:
Dr. Anupam Mitra, was a highly motivated and enthusiastic individual with strong academic credentials. he did MD in clinical pharmacology and have work experience in pharmacovigilance and multiple sponsored phase III clinical trials, which later got FDA approval for type II diabetes mellitus. In the quest for translational research, after MD, he worked as a postdoctoral fellow in the department of dermatology and immunology at University of California Davis Medical Center, Sacramento, CA, USA. and he also worked on studying the functional role of Th17 cytokines in the pathogenesis of autoimmune diseases and evaluated the therapeutic potential of novel vitamin-D analogs and mTOR inhibitors in psoriasis, rheumatoid arthritis, psoriatic arthritis and scleroderma. He is now currently evaluating the contribution of glycans in the pathogenesis of melanoma. Being a clinician involved in both translational research and clinical trials have given me good understanding of drug development. He wishes to pursue my career in the preclinical and clinical drug development.
×
Dr. Anupam Mitra, was a highly motivated and enthusiastic individual with strong academic credentials. he did MD in clinical pharmacology and have work experience in pharmacovigilance and multiple sponsored phase III clinical trials, which later got FDA approval for type II diabetes mellitus. In the quest for translational research, after MD, he worked as a postdoctoral fellow in the department of dermatology and immunology at University of California Davis Medical Center, Sacramento, CA, USA. and he also worked on studying the functional role of Th17 cytokines in the pathogenesis of autoimmune diseases and evaluated the therapeutic potential of novel vitamin-D analogs and mTOR inhibitors in psoriasis, rheumatoid arthritis, psoriatic arthritis and scleroderma. He is now currently evaluating the contribution of glycans in the pathogenesis of melanoma. Being a clinician involved in both translational research and clinical trials have given me good understanding of drug development. He wishes to pursue my career in the preclinical and clinical drug development.
Ramesh Thylur
Pennsylvania University
USA View Profile
Research Interest:
Cell death/Apoptosis; Cytoskeleton/cell adhesion/cell migration; Cancer; Gene regulation; Immunology/Infectious disease; Signal transduction
Cell death/Apoptosis; Cytoskeleton/cell adhesion/cell migration; Cancer; Gene regulation; Immunology/Infectious disease; Signal transduction
Profile:
Ramesh Thylur is a Postdoctoral Fellow in the Department of Biochemistry and Molecular Biology, Penn State College of Medicine, Pennsylvania University, Hershey, USA. He received his PhD Degree in Medicine at Kyungpook National University, Republic of Korea. During his pre- and post-doctoral training, he worked in molecular immunology and cell biology at Gwangju Institute of Science and Technology, Republic of Korea and in prostate cancer biology at Loyola University Medical Center, Chicago, USA. He worked as a Group leader at Drug discovery division of Skanda Lifesciences Pvt Ltd, India. His research is focused on cerebral malaria, one of the main health problems facing developing countries today. At present, preventative and treatment strategies are continuously hampered by the issues of the ever-emerging parasite resistance to newly introduced drugs, considerable costs and logistical problems. The main hope for changing this situation would be the development of effective malaria vaccines. An important part of this process understands the mechanisms of naturally acquired immunity to malaria. My focus is to understand the malaria parasite Plasmodium falciparum-host interactions and signaling mechanisms involved in the development of protective immunity to malaria and in malaria pathogenesis. Here asking how cytokine administration or inhibition of MAPK signaling protects cerebral malaria by controlling parasitaemia, pro-inflammatory responses, decreasing the infiltration of lymphocytes to the brain and modulating innate and adaptive immune responses, in order to develop next generation of therapeutic agents to eradicate malaria.
×
Ramesh Thylur is a Postdoctoral Fellow in the Department of Biochemistry and Molecular Biology, Penn State College of Medicine, Pennsylvania University, Hershey, USA. He received his PhD Degree in Medicine at Kyungpook National University, Republic of Korea. During his pre- and post-doctoral training, he worked in molecular immunology and cell biology at Gwangju Institute of Science and Technology, Republic of Korea and in prostate cancer biology at Loyola University Medical Center, Chicago, USA. He worked as a Group leader at Drug discovery division of Skanda Lifesciences Pvt Ltd, India. His research is focused on cerebral malaria, one of the main health problems facing developing countries today. At present, preventative and treatment strategies are continuously hampered by the issues of the ever-emerging parasite resistance to newly introduced drugs, considerable costs and logistical problems. The main hope for changing this situation would be the development of effective malaria vaccines. An important part of this process understands the mechanisms of naturally acquired immunity to malaria. My focus is to understand the malaria parasite Plasmodium falciparum-host interactions and signaling mechanisms involved in the development of protective immunity to malaria and in malaria pathogenesis. Here asking how cytokine administration or inhibition of MAPK signaling protects cerebral malaria by controlling parasitaemia, pro-inflammatory responses, decreasing the infiltration of lymphocytes to the brain and modulating innate and adaptive immune responses, in order to develop next generation of therapeutic agents to eradicate malaria.
Elisabetta Mantuano
University of California
USA View Profile
Research Interest:
Identifying and characterizing novel pathways by which proteases and their cell-surface receptors regulate cell physiology; determining the function of protease receptors in projects related to peripheral nerve injury, Neurodegenerative diseases; Innate immunity and inflammatory responses; studying the role of neurotrophic factors in neuronal development and axonal regeneration in the intact and injured peripheral nervous system, along with identifying strategies to enhance axonal regeneration after acute and chronic spinal cord injury, models of pain and neuropathic pain behavior.
Identifying and characterizing novel pathways by which proteases and their cell-surface receptors regulate cell physiology; determining the function of protease receptors in projects related to peripheral nerve injury, Neurodegenerative diseases; Innate immunity and inflammatory responses; studying the role of neurotrophic factors in neuronal development and axonal regeneration in the intact and injured peripheral nervous system, along with identifying strategies to enhance axonal regeneration after acute and chronic spinal cord injury, models of pain and neuropathic pain behavior.
Profile:
Elisabetta Mantuano holds a Pharm.D. with a Ph.D. in Medicinal Chemistry from University of Pisa in Italy. She did her residency training in Neuroscience and Clinical Pharmacology in Italy at the Department of Human Physiology and Pharmacology in Sapienza University of Rome. During her post doctoral fellowship at the Department of Anesthesiology at the University of California San Diego, she planned and conducted many of the important studies that implicated LDL Receptorrelated Protein-1 (LRP1) in Schwann cell survival and in Schwann cell-axonal interactions that are critical for peripheral nerve function. She generated novel molecular constructs, which encode fragments of the protease, MMP-9, which retain the ability to bind to LRP1, and she established the breeding protocols to generate the first transgenic mice in which LRP1 is conditionally deleted in Schwann cells. In late 2011, she accepted a position as Associate Project Scientist in the Department of Pathology at the University of California San Diego where she has been working in signaling pathways involved in neurodegenerative diseases, peripheral nerve injury, innate immunity, cancer angiogenesis and inflammatory responses. She is currently an Assistant Professor at Sapienza University of Rome and she has been working as the research supervisor of the International Research Laboratory between Sapienza University of Rome and the University of California San Diego. She published research articles in top-tier national and international scientific journals, such as Journal of Neuroscience, PNAS, Journal of Biological Chemistry, Journal of Cell Science and Science Signaling. In the past years she has gained considerable experience in mentoring undergraduate and PhD students, research technicians and Postdocs. All of this experience has provided her with the expertise, leadership, and skills necessary to successfully carry out different kinds of research programs.
×
Elisabetta Mantuano holds a Pharm.D. with a Ph.D. in Medicinal Chemistry from University of Pisa in Italy. She did her residency training in Neuroscience and Clinical Pharmacology in Italy at the Department of Human Physiology and Pharmacology in Sapienza University of Rome. During her post doctoral fellowship at the Department of Anesthesiology at the University of California San Diego, she planned and conducted many of the important studies that implicated LDL Receptorrelated Protein-1 (LRP1) in Schwann cell survival and in Schwann cell-axonal interactions that are critical for peripheral nerve function. She generated novel molecular constructs, which encode fragments of the protease, MMP-9, which retain the ability to bind to LRP1, and she established the breeding protocols to generate the first transgenic mice in which LRP1 is conditionally deleted in Schwann cells. In late 2011, she accepted a position as Associate Project Scientist in the Department of Pathology at the University of California San Diego where she has been working in signaling pathways involved in neurodegenerative diseases, peripheral nerve injury, innate immunity, cancer angiogenesis and inflammatory responses. She is currently an Assistant Professor at Sapienza University of Rome and she has been working as the research supervisor of the International Research Laboratory between Sapienza University of Rome and the University of California San Diego. She published research articles in top-tier national and international scientific journals, such as Journal of Neuroscience, PNAS, Journal of Biological Chemistry, Journal of Cell Science and Science Signaling. In the past years she has gained considerable experience in mentoring undergraduate and PhD students, research technicians and Postdocs. All of this experience has provided her with the expertise, leadership, and skills necessary to successfully carry out different kinds of research programs.
Maria L Mancini
Vice President of Pharmacology
USA View Profile
Research Interest:
Research performed at Champions Oncology focuses on the development of advanced biotechnology solutions to personalize the development and use of oncology drugs.
Research performed at Champions Oncology focuses on the development of advanced biotechnology solutions to personalize the development and use of oncology drugs.
Profile:
Dr. Mancini Maria, was a highly motivated scientist with the expertise, leadership, and training necessary to successfully carry out the proposed research project. she have a broad background in basic and translational oncology research with specific training and expertise in studying the genetic basis of cancer development and progression. she have extensively studied therapeutic responses in human tumors as well as the mechanisms of systemic toxicity associated with these treatments. Her previous research and training is now combined with the mission of Champions Oncology to utilize patient derived xenografts (PDX) in a translational way using our TumorgraftsTM to understand how the genetic signatures of individual tumors and cancer types can best inform treatment through patient stratification. A critical part of this is to strategically build and characterize tumor models in our PDX bank that represent the biological differences among ethnic groups both within and across cancer types. As the Director of Translational Oncology she lead the development, characterization and subsequent drug testing of patient tumors in our PDX platform as well as new technology development.
×
Dr. Mancini Maria, was a highly motivated scientist with the expertise, leadership, and training necessary to successfully carry out the proposed research project. she have a broad background in basic and translational oncology research with specific training and expertise in studying the genetic basis of cancer development and progression. she have extensively studied therapeutic responses in human tumors as well as the mechanisms of systemic toxicity associated with these treatments. Her previous research and training is now combined with the mission of Champions Oncology to utilize patient derived xenografts (PDX) in a translational way using our TumorgraftsTM to understand how the genetic signatures of individual tumors and cancer types can best inform treatment through patient stratification. A critical part of this is to strategically build and characterize tumor models in our PDX bank that represent the biological differences among ethnic groups both within and across cancer types. As the Director of Translational Oncology she lead the development, characterization and subsequent drug testing of patient tumors in our PDX platform as well as new technology development.
Luisetto Mauro
Turin University
Italy View Profile
Research Interest:
Pharmacology; Toxicology; Neuroscience; Pathology
Pharmacology; Toxicology; Neuroscience; Pathology
Profile:
Dr. Mauro Luisetto, obtained his Pharm D in 1995 from the Turin University and worked as European specialist in laboratory medicine. Currently, he works as Public Hospital Pharmacist Manager and is responsible of hospital medicinal gas quality control PC HOSP. He is also the Director of hospital medicinal gases contract implementation. His working filed and rotation is biochemistry, toxicology, blood bank, haematology. microbiology; hospital pharmacy (drugs logistic, galenic, medicinal gas quality controller , radio drugs, rx contrast agents, departmental pharmacist); clinical pathology, antidothes responsible stokes provincial PC, logistic of diagnostic in vitro), responsible for emergency drug hospital stokes.
×
Dr. Mauro Luisetto, obtained his Pharm D in 1995 from the Turin University and worked as European specialist in laboratory medicine. Currently, he works as Public Hospital Pharmacist Manager and is responsible of hospital medicinal gas quality control PC HOSP. He is also the Director of hospital medicinal gases contract implementation. His working filed and rotation is biochemistry, toxicology, blood bank, haematology. microbiology; hospital pharmacy (drugs logistic, galenic, medicinal gas quality controller , radio drugs, rx contrast agents, departmental pharmacist); clinical pathology, antidothes responsible stokes provincial PC, logistic of diagnostic in vitro), responsible for emergency drug hospital stokes.
Gopal Krishna
Director of Clinical Pharmacology
USA View Profile
Research Interest:
Clinical Pharmacology; clinical trials; Exposure-Response and Model Based Drug Development, Drug Metabolism and Pharmacokinetics
Clinical Pharmacology; clinical trials; Exposure-Response and Model Based Drug Development, Drug Metabolism and Pharmacokinetics
Profile:
Dr. Gopal Krishna is a Director, Clinical Pharmacology, at Celgene Pharmaceutical. Prior to joining Celgene, he was at Cubist (now Merck) and Merck, in the positions of increasing responsibilities. At Cubist, as a Director of Clinical Pharmacology, he led Clinical Pharmacology worldwide submission efforts for a combination product leading to approval of ceftolozane/tazobactam (Zerbaxa). he received his PhD in Pharmaceutical Sciences from Medical College of Virginia, Virginia Commonwealth University, receiving John Wood Award for excellence in Graduate Studies. He has more than 20 years of experience in Pharma Industries in all phases of drug development that includes directing clinical Pharmacology aspects to generate, interpret, and integrate knowledge of clinical pharmacology and patient covariates to optimize dose/regimen and study designs. He has implemented efficient study design with decision making end points to drive discovery and development of drugs. He has broad expertise across various therapeutic areas from the lead optimization to IND, NDA/MAA, commercialization, and life cycle management including spearheading worldwide regulatory submission efforts leading to drug approvals. He has received more than 30 awards including an outstanding paper award. he has served as a chair of clinical PK-PD abstract screening committee and a mentor to graduate students and clinical pharmacology students. He is a peer reviewer for the Journals and has over 130 manuscripts, abstracts, presentations, and book chapter.
×
Dr. Gopal Krishna is a Director, Clinical Pharmacology, at Celgene Pharmaceutical. Prior to joining Celgene, he was at Cubist (now Merck) and Merck, in the positions of increasing responsibilities. At Cubist, as a Director of Clinical Pharmacology, he led Clinical Pharmacology worldwide submission efforts for a combination product leading to approval of ceftolozane/tazobactam (Zerbaxa). he received his PhD in Pharmaceutical Sciences from Medical College of Virginia, Virginia Commonwealth University, receiving John Wood Award for excellence in Graduate Studies. He has more than 20 years of experience in Pharma Industries in all phases of drug development that includes directing clinical Pharmacology aspects to generate, interpret, and integrate knowledge of clinical pharmacology and patient covariates to optimize dose/regimen and study designs. He has implemented efficient study design with decision making end points to drive discovery and development of drugs. He has broad expertise across various therapeutic areas from the lead optimization to IND, NDA/MAA, commercialization, and life cycle management including spearheading worldwide regulatory submission efforts leading to drug approvals. He has received more than 30 awards including an outstanding paper award. he has served as a chair of clinical PK-PD abstract screening committee and a mentor to graduate students and clinical pharmacology students. He is a peer reviewer for the Journals and has over 130 manuscripts, abstracts, presentations, and book chapter.
M Walid Qoronfleh
Qatar Foundation – WISH Center
QATAR View Profile
Research Interest:
Drug discovery and development; Biotechnology; Diagnostics; Protein biomarkers; Clinical genomics; Precision Medicine; and Public health
Drug discovery and development; Biotechnology; Diagnostics; Protein biomarkers; Clinical genomics; Precision Medicine; and Public health
Profile:
Dr. M. Walid Qoronfleh is currently the Director of Healthcare Research and Policy at the World Innovation Summit for Health (WISH). Immediately prior to this he was Biotechnology Development Director at Qatar Biomedical Research Institute (QBRI). Dr. Qoronfleh’s areas of research are biotechnology, diagnostics, and personalized medicine and he has over 20 years of scientific, technology, business, and commercial experience. He has held several senior management and executive positions with increasing responsibilities at GSK, Sanofi, NIH-NCI, Next Gen Sciences (VP, Personalized Medicine) and SDIX. He was the founder of three biotechnology companies and he is a co-founder and the managing director of the boutique consulting company Q3CG. He is an ad hoc reviewer for various scientific journals and a frequent speaker at international conferences. He is also editor of two journals: the Journal of Social & Economical Issues of Biotechnology and The Scientific World Journal – Proteins & Proteomics.He obtained his Ph.D. from The University of Louisville–School of Medicine, he received his MBA from Penn State University, and holds marketing certification from The University of Wisconsin–Madison.
×
Dr. M. Walid Qoronfleh is currently the Director of Healthcare Research and Policy at the World Innovation Summit for Health (WISH). Immediately prior to this he was Biotechnology Development Director at Qatar Biomedical Research Institute (QBRI). Dr. Qoronfleh’s areas of research are biotechnology, diagnostics, and personalized medicine and he has over 20 years of scientific, technology, business, and commercial experience. He has held several senior management and executive positions with increasing responsibilities at GSK, Sanofi, NIH-NCI, Next Gen Sciences (VP, Personalized Medicine) and SDIX. He was the founder of three biotechnology companies and he is a co-founder and the managing director of the boutique consulting company Q3CG. He is an ad hoc reviewer for various scientific journals and a frequent speaker at international conferences. He is also editor of two journals: the Journal of Social & Economical Issues of Biotechnology and The Scientific World Journal – Proteins & Proteomics.He obtained his Ph.D. from The University of Louisville–School of Medicine, he received his MBA from Penn State University, and holds marketing certification from The University of Wisconsin–Madison.
Badar Uddin Umar
Oxford College of Business Science and Technology
Canada View Profile
Research Interest:
Arsenicosis and chronic arsenic toxicity; Plant extracts and medicinal properties; Adverse Drug Reactions and Pharmacovigilance; Medical Education and Teaching Methodologies; Drug Addiction; Clinical Research and drug development; Clinical Trials; Pharmacology-Basic and General Principles, Autonomic and Cardiovascular Pharmacology, Psychopharmacology; Antimicrobials and Antimicrobial Resistance; Diabetes Mellitus.
Arsenicosis and chronic arsenic toxicity; Plant extracts and medicinal properties; Adverse Drug Reactions and Pharmacovigilance; Medical Education and Teaching Methodologies; Drug Addiction; Clinical Research and drug development; Clinical Trials; Pharmacology-Basic and General Principles, Autonomic and Cardiovascular Pharmacology, Psychopharmacology; Antimicrobials and Antimicrobial Resistance; Diabetes Mellitus.
Profile:
Badar Uddin Umar had his introduction to working in research at Bangabandhu Sheikh Mujib Medical University in Dhaka, Bangladesh. He worked first as a thesis student in the Pharmacology laboratory of the university on- “Effect of Hexane Extract of Spinach in The Removal of Arsenic from Tissues of Arsenic Treated Rat”. There, he fed arsenic solutions to different groups of rats and maintained them in the animal house. Later he estimated arsenic in different tissues of rats. He also extracted crude plant extracts besides different other laboratory methods like Spectrophotometric estimation of proteins, lipid per-oxidation. While at Dhaka Medical College from 2007-2010, He has worked in various research areas, including adverse drug reaction, diabetes and plant extracts, hepatoprotective role of crude plant extracts besides medical education. From 2010-2013 He headed the Department of Pharmacology in Faridpur Medical College, Bangladesh and was involved in academic activities mainly besides being a member of the Faridpur Medical College Journal Editorial Board. Later in AIMST University Malaysia He supervised both undergraduate and post graduate students research projects. He was also a member of the Human Research Ethics Board of the Faculty of Medicine there from 2013-2015. As a co-op research assistant He maintained regulatory binders, prepared and submitted IRB submissions and documents, and assisted in protocol preparation for investigator initiated studies, maintained research databases, analyzed data and assisted in preparation of manuscripts for publications during Aug–Nov 2016 at Forensic Psychiatry Research Unit of St. Joseph’s Healthcare Hamilton, ON. He holds a Bachelor of Medicine and Bachelor of Surgery (MBBS) Degree from Pakistan and a Master of Philosophy (MPhil) in Pharmacology from the Bangabandhu Sheikh Mujib Medical University, Bangladesh. He also received CRA diploma from Oxford College of Business Science and Technology, Toronto, Canada.
×
Badar Uddin Umar had his introduction to working in research at Bangabandhu Sheikh Mujib Medical University in Dhaka, Bangladesh. He worked first as a thesis student in the Pharmacology laboratory of the university on- “Effect of Hexane Extract of Spinach in The Removal of Arsenic from Tissues of Arsenic Treated Rat”. There, he fed arsenic solutions to different groups of rats and maintained them in the animal house. Later he estimated arsenic in different tissues of rats. He also extracted crude plant extracts besides different other laboratory methods like Spectrophotometric estimation of proteins, lipid per-oxidation. While at Dhaka Medical College from 2007-2010, He has worked in various research areas, including adverse drug reaction, diabetes and plant extracts, hepatoprotective role of crude plant extracts besides medical education. From 2010-2013 He headed the Department of Pharmacology in Faridpur Medical College, Bangladesh and was involved in academic activities mainly besides being a member of the Faridpur Medical College Journal Editorial Board. Later in AIMST University Malaysia He supervised both undergraduate and post graduate students research projects. He was also a member of the Human Research Ethics Board of the Faculty of Medicine there from 2013-2015. As a co-op research assistant He maintained regulatory binders, prepared and submitted IRB submissions and documents, and assisted in protocol preparation for investigator initiated studies, maintained research databases, analyzed data and assisted in preparation of manuscripts for publications during Aug–Nov 2016 at Forensic Psychiatry Research Unit of St. Joseph’s Healthcare Hamilton, ON. He holds a Bachelor of Medicine and Bachelor of Surgery (MBBS) Degree from Pakistan and a Master of Philosophy (MPhil) in Pharmacology from the Bangabandhu Sheikh Mujib Medical University, Bangladesh. He also received CRA diploma from Oxford College of Business Science and Technology, Toronto, Canada.
Maria Rosaria Carratu
University of Bari
Italy View Profile
Research Interest:
Pharmacology and Toxicology
Pharmacology and Toxicology
Profile:
Maria Rosaria Carratu born in Taranto, Italy, on February 20, 1951. Graduated in Medicine, and postgraduated in Clinical Pharmacology, she is Full Professor of Pharmacology in the School of Medicine, University of Bari “Aldo Moro”. Author of several peer-reviewed articles in the field of cellular and molecular pharmacology and toxicology. She has carried out part of her research activity in France (Laboratoire de Neurobiologie, Ecole Normale Superieure, Universite Paris VII; Laboratoire de Physiologie Cellulaire, Universite Paris XI, Orsay; Laboratoire de Toxicologie et dHygiene Appliquee, Universite Bordeaux II) and in Germany (Physiologisches Institut Universitat Krankenhaus Eppendorf, Hamburg). The research activity is now focused on the characterization of molecular targets for novel drugs in experimental models of neurodegeneration. She has been member of the Executive Committee of Italian Society of Toxicology (1996-2003) and Temporary Advisor of WHO. Directorship: Department of Pharmacology and Human Physiology, School of Medicine, University of Bari (2008-2011); PhD School in Clinical Pharmacology and Medical Therapy (2001-2014); PhD School in Biomedical Sciences and Technologies (2005-2010); post-graduate School in Medical Pharmacology (2008-2013). Membership: SIF, SITOX, SIN, EUROTOX, IUPHAR, EBRA, BDS. Professional affiliation: Medical Association, National and European Register of Toxicologists. She is serving as reviewer for Journals in the field of neuroscience and toxicology.
×
Maria Rosaria Carratu born in Taranto, Italy, on February 20, 1951. Graduated in Medicine, and postgraduated in Clinical Pharmacology, she is Full Professor of Pharmacology in the School of Medicine, University of Bari “Aldo Moro”. Author of several peer-reviewed articles in the field of cellular and molecular pharmacology and toxicology. She has carried out part of her research activity in France (Laboratoire de Neurobiologie, Ecole Normale Superieure, Universite Paris VII; Laboratoire de Physiologie Cellulaire, Universite Paris XI, Orsay; Laboratoire de Toxicologie et dHygiene Appliquee, Universite Bordeaux II) and in Germany (Physiologisches Institut Universitat Krankenhaus Eppendorf, Hamburg). The research activity is now focused on the characterization of molecular targets for novel drugs in experimental models of neurodegeneration. She has been member of the Executive Committee of Italian Society of Toxicology (1996-2003) and Temporary Advisor of WHO. Directorship: Department of Pharmacology and Human Physiology, School of Medicine, University of Bari (2008-2011); PhD School in Clinical Pharmacology and Medical Therapy (2001-2014); PhD School in Biomedical Sciences and Technologies (2005-2010); post-graduate School in Medical Pharmacology (2008-2013). Membership: SIF, SITOX, SIN, EUROTOX, IUPHAR, EBRA, BDS. Professional affiliation: Medical Association, National and European Register of Toxicologists. She is serving as reviewer for Journals in the field of neuroscience and toxicology.
Marc Rahme
University of Ottawa
Canada View Profile
Raphael Serreau
Necker University Hospital
France View Profile
Research Interest:
Clinical Pharmacology; Pregnancy and Neonatal Health Diseases; Breastfeeding; Toxicology and xenobiotics
Clinical Pharmacology; Pregnancy and Neonatal Health Diseases; Breastfeeding; Toxicology and xenobiotics
Profile:
×
Jiapu Zhang
Federation University
Australia View Profile
Research Interest:
Protein Structures and Functions; Structural Dynamics and Structure-based Drug Design; Drug Candidate Optimization
Protein Structures and Functions; Structural Dynamics and Structure-based Drug Design; Drug Candidate Optimization
Profile:
Jiapu Zhang is an Australian Research Scientist. He finished his PhD degree in Australia, one Masters (in research) degree in National University of Singapore, and one Masters (in research) degree and one Bachelor degree in China in 2004, 2000, 1996 and 1993 respectively. During 1996-1998 he lectured in Shandong University (South Campus) - a famous and top university of China. Since 2005, he has worked in Australias CSIRO (Common wealth Scientific and Industrial Research Organization), Ballarat, Melbourne and Swinburne Universities as Postdocs Research Scientist researcher. CSIRO has a team of protein structure-based drug design and successful designed the 1st drug Relenza TM in treating the flu; He was trained by this team. He has done a project on neurodegenerative diseases protein structures and functions, structural dynamics and structure-based drug design. He has also done clinical statistical analysis works.
×
Jiapu Zhang is an Australian Research Scientist. He finished his PhD degree in Australia, one Masters (in research) degree in National University of Singapore, and one Masters (in research) degree and one Bachelor degree in China in 2004, 2000, 1996 and 1993 respectively. During 1996-1998 he lectured in Shandong University (South Campus) - a famous and top university of China. Since 2005, he has worked in Australias CSIRO (Common wealth Scientific and Industrial Research Organization), Ballarat, Melbourne and Swinburne Universities as Postdocs Research Scientist researcher. CSIRO has a team of protein structure-based drug design and successful designed the 1st drug Relenza TM in treating the flu; He was trained by this team. He has done a project on neurodegenerative diseases protein structures and functions, structural dynamics and structure-based drug design. He has also done clinical statistical analysis works.
Laino Carlos Horacio
National University of La Rioja
Argentina View Profile
Research Interest:
Biotechnology; pharmacology and drug discovery in the field of pain; depression and anxiety
Biotechnology; pharmacology and drug discovery in the field of pain; depression and anxiety
Profile:
Dr. Laino was Director of the Biotechnology Institute and Associate Professor at the Pharmacology & Toxicology Department, Faculty of Pharmacy and Biochemistry, National University of La Rioja, Argentina. His is the Director of National System of Pharmacovigilance in La Rioja Province -National Administration of Drugs, Food and Medical Devices (ANMAT), Argentina. He completed her Degree in Biochemistry (National University of Cordoba, Argentina), MSc (Toronto, Canada) and Doctorate degree in Pharmacology with honors from University of Buenos Aires, Argentina. His main research is focused on the design, development and discovery of a new drug, a new combination of standard treatments, or new doses of current therapies. The Biotechnology Institute applies animal models for drug discovery research in the field of pain, depression and anxiety. Research from his laboratory was supported by funds from the Ministry of Science and Technology of the Nation and currently by numerous grants from National University of La Rioja. His research work has been documented in numerous patents, peer-reviewed publications, books chapters, oral presentations, abstracts and conference proceedings.
×
Dr. Laino was Director of the Biotechnology Institute and Associate Professor at the Pharmacology & Toxicology Department, Faculty of Pharmacy and Biochemistry, National University of La Rioja, Argentina. His is the Director of National System of Pharmacovigilance in La Rioja Province -National Administration of Drugs, Food and Medical Devices (ANMAT), Argentina. He completed her Degree in Biochemistry (National University of Cordoba, Argentina), MSc (Toronto, Canada) and Doctorate degree in Pharmacology with honors from University of Buenos Aires, Argentina. His main research is focused on the design, development and discovery of a new drug, a new combination of standard treatments, or new doses of current therapies. The Biotechnology Institute applies animal models for drug discovery research in the field of pain, depression and anxiety. Research from his laboratory was supported by funds from the Ministry of Science and Technology of the Nation and currently by numerous grants from National University of La Rioja. His research work has been documented in numerous patents, peer-reviewed publications, books chapters, oral presentations, abstracts and conference proceedings.
Christopher Busby
Green Audit
England View Profile
Research Interest:
Ionizing radiation and health; Paediatric and cancer epidemiology; Mode of operation of living systems at the molecular cell level
Ionizing radiation and health; Paediatric and cancer epidemiology; Mode of operation of living systems at the molecular cell level
Profile:
Christopher Busby was born in Devon UK but raised in India and Africa. He qualified in Chemical Physics at the University of London and University of Kent, and worked on the molecular physical chemistry of living cells for the Wellcome Foundation, work which he still carries on from the Green Audit laboratories in Pontypool, South Wales. He most known forhis controversial work on the health effects of ionizing radiation; he is the Scientific Secretary of the European Committee on Radiation Risk based in Brussels and has edited many of its publications since its founding in 1998. He has published many research articles and books on the effects of ionizing radiation and has held a number of honorary University positions, including Visiting Professor in the Faculty of Health of the University of Ulster.
×
Christopher Busby was born in Devon UK but raised in India and Africa. He qualified in Chemical Physics at the University of London and University of Kent, and worked on the molecular physical chemistry of living cells for the Wellcome Foundation, work which he still carries on from the Green Audit laboratories in Pontypool, South Wales. He most known forhis controversial work on the health effects of ionizing radiation; he is the Scientific Secretary of the European Committee on Radiation Risk based in Brussels and has edited many of its publications since its founding in 1998. He has published many research articles and books on the effects of ionizing radiation and has held a number of honorary University positions, including Visiting Professor in the Faculty of Health of the University of Ulster.
Yousef Ahamed Yousef Alomi
Ministry of Health Saudi Arabia
Saudi Arabia View Profile
Research Interest:
Clinical Pharmacy; Total Parentral Nutrition; Pharmacy Practice; Pharmacy Administration; Drug Information Services; Drug Utilization Evaluation; Pharmaco Economic; Pharmacoepidemiology; Critical Care Pharmacy; Medication Safety
Clinical Pharmacy; Total Parentral Nutrition; Pharmacy Practice; Pharmacy Administration; Drug Information Services; Drug Utilization Evaluation; Pharmaco Economic; Pharmacoepidemiology; Critical Care Pharmacy; Medication Safety
Profile:
Yousef Alomi, General Manager of General Administration of Pharmaceutical Care, Head of Pharmacy R & D Administration and Head of Pharmacy Publications at MOH Saudi Arabia. He got his degree of Bachelor of Pharmaceutical Sciences in the year 1992 from King Saud University. After six-years of higher study, he earned his Master of Clinical Pharmacy from the same university in the 1998. He is an affiliated clinical instructor of Purdue University in the USA. He is adjunct assistant professor of King Saud University college of Pharmacy. He was a member of Pharmacy Board at Saudi commission for health Specialties for 1998-2002 and 2008-2012 and Head of Pharmacy Accreditation committee in 2010-2012. He was team member of establishing 1st Pharmacy Residency Program in Saudi Arabia. In the year 2005 he obtained Board Certification of Pharmacotherapy Specialist (BCPS). In the year 2008, he obtained his diploma in business administration from American University in Egypt in 2007, and he obtained a Board Certification of Nutrition Support Pharmacy (BCNSP) in 2009. He worked as clinical pharmacist in critical care area and nutrition support. He established and implemented several programs at MOH Hospitals at first time; Clinical Pharmacy Program, Medication Safety Program, Pain Management Program, Anticoagulation Program and Pharmacy Infection Control, including 30 Adult and 20 Pediatrics Clinical Pharmacy Program; he founder of Mass Gathering Pharmaceutical Care and Pharmacy Infection Control in Saudi Arabia. He became a member of advisory board of the Arab Pharmaceutical Journal in 2010. He became as editorial board of Journal of Pharma and Pharmaceutical Sciences in 2015, He became as editorial board of BAOJ Pharmaceutical Sciences in 2015, He became as Pharmacy Board Member of Saudi Commission of Health Care Specialities 2010-2013. He had several researches in clinical Pharmacy and Pharmacy practice published in ACCP and ISPOR conferences, He had several presentations in the clinical pharmacy and pharmacy practice at several conference in and outside Saudi Arabia.
×
Yousef Alomi, General Manager of General Administration of Pharmaceutical Care, Head of Pharmacy R & D Administration and Head of Pharmacy Publications at MOH Saudi Arabia. He got his degree of Bachelor of Pharmaceutical Sciences in the year 1992 from King Saud University. After six-years of higher study, he earned his Master of Clinical Pharmacy from the same university in the 1998. He is an affiliated clinical instructor of Purdue University in the USA. He is adjunct assistant professor of King Saud University college of Pharmacy. He was a member of Pharmacy Board at Saudi commission for health Specialties for 1998-2002 and 2008-2012 and Head of Pharmacy Accreditation committee in 2010-2012. He was team member of establishing 1st Pharmacy Residency Program in Saudi Arabia. In the year 2005 he obtained Board Certification of Pharmacotherapy Specialist (BCPS). In the year 2008, he obtained his diploma in business administration from American University in Egypt in 2007, and he obtained a Board Certification of Nutrition Support Pharmacy (BCNSP) in 2009. He worked as clinical pharmacist in critical care area and nutrition support. He established and implemented several programs at MOH Hospitals at first time; Clinical Pharmacy Program, Medication Safety Program, Pain Management Program, Anticoagulation Program and Pharmacy Infection Control, including 30 Adult and 20 Pediatrics Clinical Pharmacy Program; he founder of Mass Gathering Pharmaceutical Care and Pharmacy Infection Control in Saudi Arabia. He became a member of advisory board of the Arab Pharmaceutical Journal in 2010. He became as editorial board of Journal of Pharma and Pharmaceutical Sciences in 2015, He became as editorial board of BAOJ Pharmaceutical Sciences in 2015, He became as Pharmacy Board Member of Saudi Commission of Health Care Specialities 2010-2013. He had several researches in clinical Pharmacy and Pharmacy practice published in ACCP and ISPOR conferences, He had several presentations in the clinical pharmacy and pharmacy practice at several conference in and outside Saudi Arabia.
Mohamed Abdel Daim
Suez Canal University
Egypt View Profile
Research Interest:
Pharmacology; Toxicology; Alternative Medicine.
Pharmacology; Toxicology; Alternative Medicine.
Profile:
Mohamed Abdel-Daim is an associate professor of Pharmacology, Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt. He published many manuscripts in experimental and food animals at many scientific journals related to Pharmacology, Drug Toxicology, Biochemistry, Clinical pathology and Molecular Biology. He is currently a member of Research Ethics Council, Academy of Scientific Research & Technology, Egypt. He has high experience in revision activities in more than 100 scientific journals.
×
Mohamed Abdel-Daim is an associate professor of Pharmacology, Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt. He published many manuscripts in experimental and food animals at many scientific journals related to Pharmacology, Drug Toxicology, Biochemistry, Clinical pathology and Molecular Biology. He is currently a member of Research Ethics Council, Academy of Scientific Research & Technology, Egypt. He has high experience in revision activities in more than 100 scientific journals.
Gerti Tashko
Rockville Internal Medicine Group
USA View Profile
Research Interest:
Metabolic Syndrome (Syndrome X); Diabetes Type 1, Type 2; LADA, Latent Autoimmune Diabetes of Adults Prediabetes / Insulin Resistance; Lipids; Hypertension; Polycystic Ovarian Syndrome; Hypothyroid / Hyperthyroid / Thyroiditis; Thyroid Nodules / Cancer; Osteoporosis / Osteopenia; Parathyroid Disorders; Low Testosterone in Men and Women; Pituitary Anomalies; Adrenal Conditions; Endocrine Disorders
Metabolic Syndrome (Syndrome X); Diabetes Type 1, Type 2; LADA, Latent Autoimmune Diabetes of Adults Prediabetes / Insulin Resistance; Lipids; Hypertension; Polycystic Ovarian Syndrome; Hypothyroid / Hyperthyroid / Thyroiditis; Thyroid Nodules / Cancer; Osteoporosis / Osteopenia; Parathyroid Disorders; Low Testosterone in Men and Women; Pituitary Anomalies; Adrenal Conditions; Endocrine Disorders
Profile:
×
Mariam Ahmed
Centre of Drug Evaluation and Research
Egypt View Profile
Research Interest:
Clinical Pharmacology; Pharmacokinetics; Pharmacodynamics; Pharmacometrics (PK/PD modeling and simulations); Clinical Drug Development in Neurology; Neuro-Clinical Pharmacology; Drug-Drug Interaction (DDI); Infectious diseases; Congenital Adrenal Hyperplasia; Rare Diseases; Clinical Trial Design and Analysis; Biostatistics
Clinical Pharmacology; Pharmacokinetics; Pharmacodynamics; Pharmacometrics (PK/PD modeling and simulations); Clinical Drug Development in Neurology; Neuro-Clinical Pharmacology; Drug-Drug Interaction (DDI); Infectious diseases; Congenital Adrenal Hyperplasia; Rare Diseases; Clinical Trial Design and Analysis; Biostatistics
Profile:
Mariam Ahmed has a pharmacy background from Helwan University, Egypt. She also finished her Masters degree in Clinical Pharmacokinetics from the same University in Egypt. She completed her doctoral studies in the application of quantitative clinical pharmacology in rare diseases, with a minor in biostatistics from University of Minnesota, USA. She published several papers and abstracts. She is currently working as a fellow in the Center of Drug Evaluation and Research at Food and Drug Administration, USA.
×
Mariam Ahmed has a pharmacy background from Helwan University, Egypt. She also finished her Masters degree in Clinical Pharmacokinetics from the same University in Egypt. She completed her doctoral studies in the application of quantitative clinical pharmacology in rare diseases, with a minor in biostatistics from University of Minnesota, USA. She published several papers and abstracts. She is currently working as a fellow in the Center of Drug Evaluation and Research at Food and Drug Administration, USA.
Olga Maria Palomino
University Cmplutense Madrid
Spain View Profile
Research Interest:
Pharmacognosy; Phytochemistry; Pharmacology
Pharmacognosy; Phytochemistry; Pharmacology
Profile:
Olga M Palomino is the full Professor at the Pharmacology Department, Faculty of Pharmacy. Universidad Complutense de Madrid. Madrid, Spain. She completed her Degree in Pharmacy and Doctorate degree in Pharmacy, UCM. She us expertise in Pharmacognosy, Phytochemistry and Pharmacology. Her Research line is covering the study of pharmacological activities based on the antioxidant ability of those compounds found in vegetal species with therapeutical interest, namely a) Neuroprotective activity; b) Antitumoral activity; c) Vascular protective activity; d) Chemical analysis: identification, isolation and characterization of the active compounds mainly by Chromatographic methods. She is the author of 10 book chapters and she has 30 publications in journals with selective editorial police. She is author of more than 50 communications to Conferences, 2 supervised and concluded Master’s dissertations and 1 supervised and concluded PhD thesis. 2 PhD Thesis in progress. She has participated in 14 research grants. She is the member of the Working Party on Community Monographs and Community List (MLWP). EMA, London (Great Britain) since May, 2011. She is the expert of the Spanish National Agency for Medicinal Agents. Ministry of Health (Spain) since May, 2011. She is the peer reviewer for the Elsevier Journal Food Chemistry (Elsevier Limited, Oxford, Great Britain) since 2011. She is the foreign member of the Commission of Medical Sciences of Polish Academy of Sciences Branch in Lublin (Academic Course 2013-2014)
×
Olga M Palomino is the full Professor at the Pharmacology Department, Faculty of Pharmacy. Universidad Complutense de Madrid. Madrid, Spain. She completed her Degree in Pharmacy and Doctorate degree in Pharmacy, UCM. She us expertise in Pharmacognosy, Phytochemistry and Pharmacology. Her Research line is covering the study of pharmacological activities based on the antioxidant ability of those compounds found in vegetal species with therapeutical interest, namely a) Neuroprotective activity; b) Antitumoral activity; c) Vascular protective activity; d) Chemical analysis: identification, isolation and characterization of the active compounds mainly by Chromatographic methods. She is the author of 10 book chapters and she has 30 publications in journals with selective editorial police. She is author of more than 50 communications to Conferences, 2 supervised and concluded Master’s dissertations and 1 supervised and concluded PhD thesis. 2 PhD Thesis in progress. She has participated in 14 research grants. She is the member of the Working Party on Community Monographs and Community List (MLWP). EMA, London (Great Britain) since May, 2011. She is the expert of the Spanish National Agency for Medicinal Agents. Ministry of Health (Spain) since May, 2011. She is the peer reviewer for the Elsevier Journal Food Chemistry (Elsevier Limited, Oxford, Great Britain) since 2011. She is the foreign member of the Commission of Medical Sciences of Polish Academy of Sciences Branch in Lublin (Academic Course 2013-2014)
Nasser M Rizk
Qatar University
Qatar View Profile
Cengiz Mordeniz
Dicle University
Turkey View Profile
Research Interest:
Pain; Cognition; Informational medicine; Bioresonance; Homeopathy and Quantum medicine
Pain; Cognition; Informational medicine; Bioresonance; Homeopathy and Quantum medicine
Profile:
Dr. Cengiz Mordeniz was born in 03/11/1961 in Malatya, Eastern Turkey. For middle school, I studied at Galatasaray High School (the oldest school in Turkey with French education, )in Istanbul, Turkey, then he had transferred to Science School in Ankara, Turkey, For senior year I went to Pensacola, Gonzales, Fla, USA, with AFS scholarship and I graduated from hihg school from tate High School. For University, I attended, Medical Faculty of İstanbul, and following, I am specailized in Anesthesiology, Intensive Care and Pain medicine. I had on eyear fellowsip in Rigs Hospitalet, Copenhagen, from Danish Ministry, 1 month in Essen University from Turkish-German Medical Foundation, 3 months in Heilderberg University, from Turkish Higher Education Council, 1 week in Plovdiv University in Bulgaria, 1 week in Quantum Medical association, in Moscow, Russia. he have worked in Dicle University, Diyarbakır, Harran University, Sanliurfa and Namık Kemal University, Tekirdag. He was graduated from Homeopathy education at Medipol University, İstanbul and master of Science at Medical Law and Ethics at Acibadem University.
×
Dr. Cengiz Mordeniz was born in 03/11/1961 in Malatya, Eastern Turkey. For middle school, I studied at Galatasaray High School (the oldest school in Turkey with French education, )in Istanbul, Turkey, then he had transferred to Science School in Ankara, Turkey, For senior year I went to Pensacola, Gonzales, Fla, USA, with AFS scholarship and I graduated from hihg school from tate High School. For University, I attended, Medical Faculty of İstanbul, and following, I am specailized in Anesthesiology, Intensive Care and Pain medicine. I had on eyear fellowsip in Rigs Hospitalet, Copenhagen, from Danish Ministry, 1 month in Essen University from Turkish-German Medical Foundation, 3 months in Heilderberg University, from Turkish Higher Education Council, 1 week in Plovdiv University in Bulgaria, 1 week in Quantum Medical association, in Moscow, Russia. he have worked in Dicle University, Diyarbakır, Harran University, Sanliurfa and Namık Kemal University, Tekirdag. He was graduated from Homeopathy education at Medipol University, İstanbul and master of Science at Medical Law and Ethics at Acibadem University.
Mohamed Sayed Ahmed
Mansoura University
Egypt View Profile
Research Interest:
Pathogenesis and diagnosis of Infectious Diseases
Pathogenesis and diagnosis of Infectious Diseases
Profile:
Sayed-Ahmed holds a Bachelor’s Degree in Veterinary Medical Science from University of Mansoura in Egypt, as well as Master’s Degree in Infectious Diseases, Epidemiology and Veterinary public health from the same university. He awards his PhD in gene therapy and viral oncolysis from TIHO, Germany. Since 2011. He is Assistant Professor at the Department of Infectious Diseases, College of Veterinary Medicine, Mansoura, Egypt. He is currently Associate Professor of Pathology at Department of clinical Pharmacy, College of Pharmacy, Saudi Arabia. His main area of research is on the pathogenesis and diagnosis of Infectious Diseases. He is a member of ESVP ECVP, and ESTP. He is an editor in International journals, reviewer of more than 10 scientific journals and has over 20 publications as journal manuscripts. He joined many international conferences in Germany, Sweden, and USA. He is the author or co-author of over 20 manuscripts related to basic and clinical research, and Veterinary public health.
×
Sayed-Ahmed holds a Bachelor’s Degree in Veterinary Medical Science from University of Mansoura in Egypt, as well as Master’s Degree in Infectious Diseases, Epidemiology and Veterinary public health from the same university. He awards his PhD in gene therapy and viral oncolysis from TIHO, Germany. Since 2011. He is Assistant Professor at the Department of Infectious Diseases, College of Veterinary Medicine, Mansoura, Egypt. He is currently Associate Professor of Pathology at Department of clinical Pharmacy, College of Pharmacy, Saudi Arabia. His main area of research is on the pathogenesis and diagnosis of Infectious Diseases. He is a member of ESVP ECVP, and ESTP. He is an editor in International journals, reviewer of more than 10 scientific journals and has over 20 publications as journal manuscripts. He joined many international conferences in Germany, Sweden, and USA. He is the author or co-author of over 20 manuscripts related to basic and clinical research, and Veterinary public health.
Ibrahim Aboyadak
National Institute of Oceanography and Fishery
Egypt View Profile
Research Interest:
Veterinary Pharmacology; Aquaculture Pharmacology; Chemotherapy; Treatment of Bacterial, Fungal And Parasitic Infection
Veterinary Pharmacology; Aquaculture Pharmacology; Chemotherapy; Treatment of Bacterial, Fungal And Parasitic Infection
Profile:
Ibrahim Aboyadak was born in August 1978, earned Bachelor of veterinary medicine science, Tanta University, Egypt in 2001,Diploma in animal microbiology, Mansura University 2009, master degree in veterinary medicine science (Veterinary Pharmacology-Aquaculture Pharmacology), Kafrelsheikh University, Egypt in 2011 and Doctorate of Philosophy (Ph.D) in veterinary medicine science, (Veterinary Pharmacology-Aquaculture Pharmacology) Kafrelsheikh University, Egypt in 2014. Current job is specialist in fish disease lab at National institute of Oceanography and fishery, Alexandria, Egypt. Previous job was Head of fish diseases department in Veterinary medicine directorate of Kafrelsheikh. He assists in the experimental work of a number of masters and doctoral theses and researches in veterinary pharmacology and fish diseases and management. He also, designed and developed research plans for number of theses and scientific researches.
×
Ibrahim Aboyadak was born in August 1978, earned Bachelor of veterinary medicine science, Tanta University, Egypt in 2001,Diploma in animal microbiology, Mansura University 2009, master degree in veterinary medicine science (Veterinary Pharmacology-Aquaculture Pharmacology), Kafrelsheikh University, Egypt in 2011 and Doctorate of Philosophy (Ph.D) in veterinary medicine science, (Veterinary Pharmacology-Aquaculture Pharmacology) Kafrelsheikh University, Egypt in 2014. Current job is specialist in fish disease lab at National institute of Oceanography and fishery, Alexandria, Egypt. Previous job was Head of fish diseases department in Veterinary medicine directorate of Kafrelsheikh. He assists in the experimental work of a number of masters and doctoral theses and researches in veterinary pharmacology and fish diseases and management. He also, designed and developed research plans for number of theses and scientific researches.
Marisol S Castaneto
Forensic Toxicology Drug Testing Laboratory
USA View Profile
Research Interest:
Metabolic profiling of novel psychoactive substances; drug-drug interaction; drug addiction treatment; drug-receptor binding and mechanism of action; workplace drug testing and human sports performance testing; US and international drug policy
Metabolic profiling of novel psychoactive substances; drug-drug interaction; drug addiction treatment; drug-receptor binding and mechanism of action; workplace drug testing and human sports performance testing; US and international drug policy
Profile:
Marisol Castaneto received her BS and MS in Biochemistry from Kansas State University, KS and PhD in Toxicology from University of Maryland School of Medicine. She is currently serving as a biochemist in the US Army and is the commander of the forensic toxicology drug testing laboratory in Hawaii, which tests between 700,000 to 800,000 urine specimens per year for substance of abuse. She is also an expert witness in forensic toxicology since 2008 and has testified in 100+ separation boards and court martial proceedings. She served as a Special Volunteer at the National Institute on Drug Abuse, NIH, MD between 2011 and 2015 where she studied the metabolism and detection of novel psychoactive substances such as synthetic cannabinoids, synthetic cathinones, designer piperazines, and amphetamine analogs in urine by hyphenated-mass spectrometer methods. She also involved in training military commanders in the area of substance abuse prevention and deterrence. She is also trained in Lean Six Sigma (Black and Green Belt) and a big proponent of Quality Assurance and Quality Improvement in both forensic and clinical laboratories.
×
Marisol Castaneto received her BS and MS in Biochemistry from Kansas State University, KS and PhD in Toxicology from University of Maryland School of Medicine. She is currently serving as a biochemist in the US Army and is the commander of the forensic toxicology drug testing laboratory in Hawaii, which tests between 700,000 to 800,000 urine specimens per year for substance of abuse. She is also an expert witness in forensic toxicology since 2008 and has testified in 100+ separation boards and court martial proceedings. She served as a Special Volunteer at the National Institute on Drug Abuse, NIH, MD between 2011 and 2015 where she studied the metabolism and detection of novel psychoactive substances such as synthetic cannabinoids, synthetic cathinones, designer piperazines, and amphetamine analogs in urine by hyphenated-mass spectrometer methods. She also involved in training military commanders in the area of substance abuse prevention and deterrence. She is also trained in Lean Six Sigma (Black and Green Belt) and a big proponent of Quality Assurance and Quality Improvement in both forensic and clinical laboratories.
Mohammed S Razzaque
Harvard School of Dental Medicine
USA View Profile
Khalid Aftab
Jinnah Medical and Dental College
Pakistan View Profile
Research Interest:
Drug discovery and the scientific evaluation of traditional remedies used in different disorders
Drug discovery and the scientific evaluation of traditional remedies used in different disorders
Profile:
Khalid Aftab, Ph.D. male, Pharmacologist, graduated from department of Pharmacology, faculty of Pharmacy, University of Karachi, Pakistan in 1995. He worked for Pharmaceuticals industry as quality control & quality assurance professional and was actively involved in research & development of Pharmaceutical preparations. He has worked in few Medical & Dental Colleges & Universities as Assistant, Associate and became full Professor Pharmacology in 2006 and worked as visiting Professor in different Universities & research institutions. From 2009 - 2011, he worked in Kingdom Saudi Arabia as a full Professor Pharmacology and currently working as Professor & HoD Pharmacology in ATMC, Isra University Karachi Campus. Karachi, Pakistan.
×
Khalid Aftab, Ph.D. male, Pharmacologist, graduated from department of Pharmacology, faculty of Pharmacy, University of Karachi, Pakistan in 1995. He worked for Pharmaceuticals industry as quality control & quality assurance professional and was actively involved in research & development of Pharmaceutical preparations. He has worked in few Medical & Dental Colleges & Universities as Assistant, Associate and became full Professor Pharmacology in 2006 and worked as visiting Professor in different Universities & research institutions. From 2009 - 2011, he worked in Kingdom Saudi Arabia as a full Professor Pharmacology and currently working as Professor & HoD Pharmacology in ATMC, Isra University Karachi Campus. Karachi, Pakistan.
Srinivasan
Madras Veterinary College
India View Profile
Research Interest:
Veterinary Pharmacology and Toxicology; Reproductive Biology; Ethnoveterinary/Alternative Medicine Pharmacology; Drug discovery from herbal source using bioinformatics tools; Zebrafish models development as an alternative model for mammalian species.
Veterinary Pharmacology and Toxicology; Reproductive Biology; Ethnoveterinary/Alternative Medicine Pharmacology; Drug discovery from herbal source using bioinformatics tools; Zebrafish models development as an alternative model for mammalian species.
Profile:
Srinivasan received his MVSc in Veterinary Pharmacology in the year 2000. He has worked as scientist in the area of drug discovery and development in various leading pharmaceutical companies in India such as DSQ Biotech Limited, ZydusCadila, Ranbaxy Research Laboratories, Biocon-Bristol Meyers-Squibb Research Center (BBRC) for 11 years. He has also earned Diplomate of American Board of Toxicology, Inc. in the year 2010. Currently he is working as a faculty in Veterinary Pharmacology and Toxicology, Madras Veterinary College, Chennai, India. He is instrumental in designing and conducting Federation of European Laboratory Animal Scientists Association training program at Madras Veterinary College which is the only centre available outside the EU to offer such course. He is also acting as the local proctor for conducting the Diplomate of the American Board of Toxicology, Inc. for India at Madras Veterinary College, Chennai. Srinivasan has received three extramural funding from Government of India to conduct research in the area of establishing PCR methods for the viral infections in laboratory animals, treatment of Polycystic Ovarian Degeneration with Siddha product, Anticancer property of a Siddha product. He has published many peer reviewed articles, published a chapter in a book, etc. He is also a visiting faculty to teach Fish Pharmacology to the Fishery College in Tamil Nadu. He is a toxicology consultant for few Pharma industries to prepare the PDE document and for academic institution to design and establish the laboratory animal house.
×
Srinivasan received his MVSc in Veterinary Pharmacology in the year 2000. He has worked as scientist in the area of drug discovery and development in various leading pharmaceutical companies in India such as DSQ Biotech Limited, ZydusCadila, Ranbaxy Research Laboratories, Biocon-Bristol Meyers-Squibb Research Center (BBRC) for 11 years. He has also earned Diplomate of American Board of Toxicology, Inc. in the year 2010. Currently he is working as a faculty in Veterinary Pharmacology and Toxicology, Madras Veterinary College, Chennai, India. He is instrumental in designing and conducting Federation of European Laboratory Animal Scientists Association training program at Madras Veterinary College which is the only centre available outside the EU to offer such course. He is also acting as the local proctor for conducting the Diplomate of the American Board of Toxicology, Inc. for India at Madras Veterinary College, Chennai. Srinivasan has received three extramural funding from Government of India to conduct research in the area of establishing PCR methods for the viral infections in laboratory animals, treatment of Polycystic Ovarian Degeneration with Siddha product, Anticancer property of a Siddha product. He has published many peer reviewed articles, published a chapter in a book, etc. He is also a visiting faculty to teach Fish Pharmacology to the Fishery College in Tamil Nadu. He is a toxicology consultant for few Pharma industries to prepare the PDE document and for academic institution to design and establish the laboratory animal house.
Vivek Lal
Tertiary Care Hospital
India View Profile
Research Interest:
centered around drug (Pharmacophore) development in Pharmaceutical R&D so that more effective & potent molecules can be designed with the least side effects; especially in cardiovascular Pharmacology; Central Nervous System and metabolic (endocrine) disorders like Diabetes Mellitus
centered around drug (Pharmacophore) development in Pharmaceutical R&D so that more effective & potent molecules can be designed with the least side effects; especially in cardiovascular Pharmacology; Central Nervous System and metabolic (endocrine) disorders like Diabetes Mellitus
Profile:
Dr. Vivek Lal Currently Heading a 400 bedded multi-specialty tertiary care hospital in India, he was Doctor of Medicine in Pharmacology with 17 years experience in the specialty. he have been actively involved with pre-clinical drug research, clinical research, hospital administration and hospital logistics support system (Pharmacy management, Equipment procurement & maintenance, turnkey projects etc). In all, he has been a medical doctor for 26 years. his expertise revolves around the training of medical graduates & post graduates (inculcating interest in rational pharmacotherapeutics), top level hospital administration including expansion projects and accreditations, so also in pre-clinical drug research involving in-vitro/in-vivo Pharmacokinetics & Pharmacodynamics. he have hands on experience in the traditional as well as the Problem Based Learning (PBL) types of medical curricula being followed in different medical schools all over the world. I have been an under-graduate and post-graduate examiner for many medical universities in India. Notably, he have initiated a mammoth toxicology &toxinology project for the Indian Armed Forces, involving the compilation & designing of a poisoning database & poisoning registry for the Indian Armed Forces Personnel & their families. On the administrative front, he effectively controlled medical staff in 200-600 bedded hospitals.
×
Dr. Vivek Lal Currently Heading a 400 bedded multi-specialty tertiary care hospital in India, he was Doctor of Medicine in Pharmacology with 17 years experience in the specialty. he have been actively involved with pre-clinical drug research, clinical research, hospital administration and hospital logistics support system (Pharmacy management, Equipment procurement & maintenance, turnkey projects etc). In all, he has been a medical doctor for 26 years. his expertise revolves around the training of medical graduates & post graduates (inculcating interest in rational pharmacotherapeutics), top level hospital administration including expansion projects and accreditations, so also in pre-clinical drug research involving in-vitro/in-vivo Pharmacokinetics & Pharmacodynamics. he have hands on experience in the traditional as well as the Problem Based Learning (PBL) types of medical curricula being followed in different medical schools all over the world. I have been an under-graduate and post-graduate examiner for many medical universities in India. Notably, he have initiated a mammoth toxicology &toxinology project for the Indian Armed Forces, involving the compilation & designing of a poisoning database & poisoning registry for the Indian Armed Forces Personnel & their families. On the administrative front, he effectively controlled medical staff in 200-600 bedded hospitals.
Suad Yousif AbdAllah Alkarib
Dean College of Pharmacy - University of Karary
Sudan View Profile
Research Interest:
pharmacology
pharmacology
Profile:
Suad Yousif Abdalla Alkarib has completed her PhD at the age of 37 years from University of Khartoum. She is the founder of College of Pharmacy in Karary University. Before she was a Director general manager for the “Wafrapharma Laboratories Ltd. She is the Member of the Sudanese Medical Council, Scientific Researches committee in Gum Arabic Board(Sudan) and Arab Administrative Development Organization(League of Arab States). She is the Rapporteur of the Industrial Pharmacy Committee in the Pan Arab Colleges of Pharmacy.(October-2012). She is also the Member of the proposed fellowship in Technology of Industrial Pharmacy. (Council of pharmaceutical specialties-Sudan). She has got a Certificate of honor as a leader in the field of pharmacy, and the first female major-general (Jan-2011) Sudan. She has got a MAJOR AWARDS AND DECORATIONS in Competency - Duty - The national Rescue - Golden defence. She attended twenty Pharmaceutical Conferences. She has published more than fourteen papers in deferent Journals and Conferences.
×
Suad Yousif Abdalla Alkarib has completed her PhD at the age of 37 years from University of Khartoum. She is the founder of College of Pharmacy in Karary University. Before she was a Director general manager for the “Wafrapharma Laboratories Ltd. She is the Member of the Sudanese Medical Council, Scientific Researches committee in Gum Arabic Board(Sudan) and Arab Administrative Development Organization(League of Arab States). She is the Rapporteur of the Industrial Pharmacy Committee in the Pan Arab Colleges of Pharmacy.(October-2012). She is also the Member of the proposed fellowship in Technology of Industrial Pharmacy. (Council of pharmaceutical specialties-Sudan). She has got a Certificate of honor as a leader in the field of pharmacy, and the first female major-general (Jan-2011) Sudan. She has got a MAJOR AWARDS AND DECORATIONS in Competency - Duty - The national Rescue - Golden defence. She attended twenty Pharmaceutical Conferences. She has published more than fourteen papers in deferent Journals and Conferences.
Adesuyi Adeyinka Leslie Ajayi
Baylor College of Medicine
USA View Profile
Research Interest:
Parasympathetic action of ACE inhibitors as a beneficial class action to reduce cardiac death and arrhythmias; Role of endogenous opioids in captopril induced hypotension; Age and ethnic difference in response to Renin Angiotensin System interaction; Mechanisms of cardiac cachexia and prevention or reversal by ACE inhibitors; Gender and the cardiovascular and platelet changes in Type 2 Diabetes -clinical and experimental
Parasympathetic action of ACE inhibitors as a beneficial class action to reduce cardiac death and arrhythmias; Role of endogenous opioids in captopril induced hypotension; Age and ethnic difference in response to Renin Angiotensin System interaction; Mechanisms of cardiac cachexia and prevention or reversal by ACE inhibitors; Gender and the cardiovascular and platelet changes in Type 2 Diabetes -clinical and experimental
Profile:
Adesuyi Adeyinka Leslie AJAYI was Graduated Medical degree from Obafemi Awolowo University, ile -ife Nigeria ( then University of Ife, Ile ife) winning the Faculty Prize, Foundation Dean Medal for best undergraduate performance, as well as the University Scholarship and State Government Merit Award for best students with First class grade performance in the first university examination. and he awarded Doctorate of Philosophy (PhD)-1985 in Pharmacology and Clinical pharmacology /cardiovascular Medicine from the Faculty of Medicine, University Department of Materia Medica, Stobhill General hospital, University of Glasgow, G12 8QQ. Research Undertaken for the development of new cardiovascular medications globally used in hypertension , Diabetes , Heart failure, Renal disease and more . These are the Angiotensin converting Enzyme inhibitors - research was supervised by Professor John L Reid , OBE, FRSE, FMED SCI, DM. FRCP. Regius Professor of Medicine, Glasgow University. and he was Member of the British Pharmacological Society in 1986, and then elected distinguished Fellow of the British Pharmacological Society in 2006 -FBPharmacolS
×
Adesuyi Adeyinka Leslie AJAYI was Graduated Medical degree from Obafemi Awolowo University, ile -ife Nigeria ( then University of Ife, Ile ife) winning the Faculty Prize, Foundation Dean Medal for best undergraduate performance, as well as the University Scholarship and State Government Merit Award for best students with First class grade performance in the first university examination. and he awarded Doctorate of Philosophy (PhD)-1985 in Pharmacology and Clinical pharmacology /cardiovascular Medicine from the Faculty of Medicine, University Department of Materia Medica, Stobhill General hospital, University of Glasgow, G12 8QQ. Research Undertaken for the development of new cardiovascular medications globally used in hypertension , Diabetes , Heart failure, Renal disease and more . These are the Angiotensin converting Enzyme inhibitors - research was supervised by Professor John L Reid , OBE, FRSE, FMED SCI, DM. FRCP. Regius Professor of Medicine, Glasgow University. and he was Member of the British Pharmacological Society in 1986, and then elected distinguished Fellow of the British Pharmacological Society in 2006 -FBPharmacolS
Eugenia Yiannakopoulou
Highest Technological Educational Institute of Athens
Greece View Profile
Leandro Bueno Bergantin
Federal University of Sao Paulo
Brazil View Profile
Research Interest:
pharmacology
pharmacology
Profile:
Dr. Bergantin received his academic education at EPM-UNIFESP (Brazil) and UAM (Spain): biomedicine (2008), MSc (2010) and PhD (2014). His research work solved the enigma of the paradoxical effects produced by L-type Ca2+ channel blockers (ScienceDirect TOP 25 Hottest Articles - Biochemistry, Genetics and Molecular Biology - Cell Calcium). Since 1975, several clinical and experimental studies have reported that acute and chronic administration of L-type Ca2+ channel blockers (CCB), such as nifedipine, produces reduction in arterial pressure associated with a paradoxical increase of sympathetic activity. In 2013, Dr. Bergantin and collaborators discovered that this paradoxical increase in sympathetic activity produced by Ltype CCB is due to interaction of the Ca2+/cAMP signaling pathways. Then, the pharmacological manipulation of this interaction could be a new therapeutic strategy for increasing neurotransmission in psychiatric disorders, and producing neuroprotection in the neurodegenerative diseases (Bergantin and Caricati-Neto, 2016 Eur J Pharmacol; Caricati- Neto et al., 2015 Pharm Res Perspect). In addition, the pharmacological handling of the Ca2+/cAMP signaling interaction could be a more efficient therapeutic approach to inhibit cancer tumor progression (Errante PR et al., 2017 Adv Cancer Prev). Dr. Bergantin has published several articles in international journals (>40), book chapters and an international book. He is member of several editorial boards of international journals (>60, including editorin- chief of 3 international journals). Dr. Bergantin has been frequently invited (every week) to be honorable guest (speaker) in international conferences, and to participating in media interviews.
×
Dr. Bergantin received his academic education at EPM-UNIFESP (Brazil) and UAM (Spain): biomedicine (2008), MSc (2010) and PhD (2014). His research work solved the enigma of the paradoxical effects produced by L-type Ca2+ channel blockers (ScienceDirect TOP 25 Hottest Articles - Biochemistry, Genetics and Molecular Biology - Cell Calcium). Since 1975, several clinical and experimental studies have reported that acute and chronic administration of L-type Ca2+ channel blockers (CCB), such as nifedipine, produces reduction in arterial pressure associated with a paradoxical increase of sympathetic activity. In 2013, Dr. Bergantin and collaborators discovered that this paradoxical increase in sympathetic activity produced by Ltype CCB is due to interaction of the Ca2+/cAMP signaling pathways. Then, the pharmacological manipulation of this interaction could be a new therapeutic strategy for increasing neurotransmission in psychiatric disorders, and producing neuroprotection in the neurodegenerative diseases (Bergantin and Caricati-Neto, 2016 Eur J Pharmacol; Caricati- Neto et al., 2015 Pharm Res Perspect). In addition, the pharmacological handling of the Ca2+/cAMP signaling interaction could be a more efficient therapeutic approach to inhibit cancer tumor progression (Errante PR et al., 2017 Adv Cancer Prev). Dr. Bergantin has published several articles in international journals (>40), book chapters and an international book. He is member of several editorial boards of international journals (>60, including editorin- chief of 3 international journals). Dr. Bergantin has been frequently invited (every week) to be honorable guest (speaker) in international conferences, and to participating in media interviews.
Panchanan Maiti
Central Michigan University
USA View Profile
Research Interest:
Protein misfolding and neurodegenerative diseases; Drug development in neurological diseases; Synaptic plasticity in neurodegenerative diseases; Stem cell therapy for neurodegenerative diseases
Protein misfolding and neurodegenerative diseases; Drug development in neurological diseases; Synaptic plasticity in neurodegenerative diseases; Stem cell therapy for neurodegenerative diseases
Profile:
Panchanan Maiti was born onJanuary 20, 1978 at Midnapur, West Bengal, India. He did his MSc on Human Physiology with Community Health at 2002. He did his PhD on neurophysiology on 2008.He also has postgraduate diploma on Medical Laboratory Technology on 2000. After completing his PhD, he moved to USA for postdoctoral study and was involved in study the cellular and molecular mechanism of neurodegenerative diseases especially Alzheimer’s, Parkinson’s and Huntington’s diseases. Currently he is a faculty member of Dept. of Psychology and Neuroscience Program, Central Michigan University, USA. He is author of several peer-reviewed articles in the field of cellular and molecular neurobiology and pharmacology. He is currently involved in developing anti-amyloid drug on Alzheimer’s and Hunting’s diseases. He is also involved in stem cell therapy in neurodegenerative diseases. He served as editorial board member of several international journals and reviewed many journal articles. He is a member of several prestigious scientific organizations in USA, Europe, Japan and India.
×
Panchanan Maiti was born onJanuary 20, 1978 at Midnapur, West Bengal, India. He did his MSc on Human Physiology with Community Health at 2002. He did his PhD on neurophysiology on 2008.He also has postgraduate diploma on Medical Laboratory Technology on 2000. After completing his PhD, he moved to USA for postdoctoral study and was involved in study the cellular and molecular mechanism of neurodegenerative diseases especially Alzheimer’s, Parkinson’s and Huntington’s diseases. Currently he is a faculty member of Dept. of Psychology and Neuroscience Program, Central Michigan University, USA. He is author of several peer-reviewed articles in the field of cellular and molecular neurobiology and pharmacology. He is currently involved in developing anti-amyloid drug on Alzheimer’s and Hunting’s diseases. He is also involved in stem cell therapy in neurodegenerative diseases. He served as editorial board member of several international journals and reviewed many journal articles. He is a member of several prestigious scientific organizations in USA, Europe, Japan and India.
Associate Editors
Nina jochnowitz
Merck Pharmaceuticals, USA
Divya A Samineni
Genentech, USA
Marshall S Scicchitano
Synergy Research Inc, USA
Charles Oo
Drug Development | Biopharmaceutics & ADME, USA
Joel L Zive
University of Florida, USA
Yasser Heakal
DYouville School of Pharmacy, USA
Ayan Ray
Icahn School of Medicine, USA
Prem Swaroop Yadav
Harvard Medical School, USA
Naeem K Patil
Vanderbilt University Medical Center, USA
Hosam A Elbaz
Ivy Tech Community College, USA
Eric A Murphy
Translational Oncology at Crown Bioscience, USA
Aymen A
University of Charleston
USA
Kowser Miah
University of Pittsburgh, USA
Vijay More
Merck, USA
HebaoYuan
University of Michigan, USA
Nisha Nanaware Kharade
Department of Clinical Pharmacology
USA
Mohamed Elmeliegy
Oncology Clinical Pharmacology
USA
Bharath Kumar
Biogen Idec
USA
M Devrim Guner
TOBB ETU Medical School
Turkey
Christine Yuying Gao
President & CEO Certara Strategic Consulting China, China
William P. Clafshenkel
Center of Research in Experimental Organogenesis (LOEX)/University Laval
Canada
Mohammed Hussain A Abutaleb
Ministry of Health Saudi Arabia, Saudi Arabia
Ibrahim Hamdy Younos
Menoufia University
Egypt
Ali Gamal Ahmed Al-kaf
sanaa university
Yemen
Ioannis Charalampopoulos
University of Crete
Greece
Christopher E Pedigo
University of Miami
Ajmal Rashid Bhat
Nagpur University, India
Sandip Mukhopadhyay
Burdwan Medical College
India
Sukanta Sen
ICARE Institute of Medical Sciences & Research Haldia
India
Shankaranarayanan Jeyakodi
Omni Active Health Technologies Ltd, India
Rishit Zalawadia
Sun Pharma Advance Research Company, India
Gandhali A Deshpande
SIRO Clinpharm Pvt. Ltd. India
Nilesh J Patel
Ganpat University, India
Bhoomika Patel
Nirma University, India
Nitibhushansingh Rajendrasingh Chandel
GMC, Rajnandgaon,C G
India
Snehasis Jana
Trivedi Science Research Laboratory, India
Kundan Prasad
School Education Govt. of Uttarakhand
India
Kailas Dnyaneshwar Ghodke
Intas Pharmaceuticals
India
Mohamed Hatem Khalil
Hikma Specialized Pharmaceuticals, Egypt
Mohd Amin Mir
uttarakhand technical university
India
Ravindra Sutar
Savitribai Phule Pune University
India
Maurya Miteshkumar Rajaram
Seth GS Medical College & KEM Hospital
India
Choudhury Mizanur Rouf
Shahjalal University of Science & Technology
Bangladesh
M Natesh Prabhu
Dhanalakshmi Srinivasan Medical College and Hospital
India
Kavitha CM
Clinical research Physician
India
Jonny Burga Sanchez
Department of Physiological Sciences of the Piracicaba Dental School - UNICAMP
Brazil
Muneeb U Rehman
Sher-e-Kashmir University of Agricultural Sciences and Technology
India
Archana Jha
National Institute of Dental and Craniofacial Research, USA
Ratnakar Deole
Northeastern State University
Oklahoma
Manuele Biazzo
Cathy D Graham
Wright State University
USA
